Hello I'm Raiyyan Tahsan
Brand Model and Executive

TC(1472).(12).ENT Department Case No (109): Radiographically Confirmed Adenoid Hypertrophy with Physician-Documented Adenotonsillitis and Possible Concurrent Otitis Media-(1 Prescription + 2 Reports).5577

đŸŠē ADENOID HYPERTROPHY — Clinical Report Analysis & Management Plan

āĻŦāĻžāĻ‚āϞāĻžāϝāĻŧ āĻŦāĻŋāĻ¸ā§āϤāĻžāϰāĻŋāϤ āϰāĻŋāĻĒā§‹āĻ°ā§āϟ āĻŦāĻŋāĻļā§āϞ⧇āώāĻŖ | Report No. 1 & Report No. 2

āφāĻĒāύāĻžāϰ āĻĻ⧇āĻ“āϝāĻŧāĻž āĻĻ⧁āϟāĻŋ āĻ›āĻŦāĻŋ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰ⧇āĻ›āĻŋāĨ¤ āĻĒā§āϰāĻĨāĻŽāϟāĻŋ Radiology Written Report āĻāĻŦāĻ‚ āĻĻā§āĻŦāĻŋāϤ⧀āϝāĻŧāϟāĻŋ Lateral Nasopharyngeal X-ray FilmāĨ¤

🔴 āϰāĻŋāĻĒā§‹āĻ°ā§āĻŸā§‡ āĻĒāĻžāĻ“āϝāĻŧāĻž āĻĒā§āϰāϧāĻžāύ āϰ⧋āĻ— āύāĻŋāĻ°ā§āĻŖāϝāĻŧ

Radiological Diagnosis: Mild to Moderate Adenoid Hypertrophy with Nasopharyngeal Airway Narrowing.

āĻŦāĻžāĻ‚āϞāĻž: āĻļāĻŋāĻļ⧁āϟāĻŋāϰ āύāĻžāϕ⧇āϰ āĻĒ⧇āĻ›āύ⧇ āĻ…āĻŦāĻ¸ā§āĻĨāĻŋāϤ āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ āϟāĻŋāĻ¸ā§āϝ⧁ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāϕ⧇āϰ āϤ⧁āϞāύāĻžāϝāĻŧ āĻŦāĻĄāĻŧ āĻšāϝāĻŧ⧇āϛ⧇āĨ¤ āĻĢāϞ⧇ āύāĻžāϕ⧇āϰ āĻĒ⧇āĻ›āύ⧇āϰ āĻļā§āĻŦāĻžāϏ āϚāϞāĻžāϚāϞ⧇āϰ āĻĒāĻĨ āĻŽā§ƒāĻĻ⧁ āĻĨ⧇āϕ⧇ āĻŽāĻžāĻāĻžāϰāĻŋ āĻŽāĻžāĻ¤ā§āϰāĻžāϝāĻŧ āϏāĻ‚āϕ⧁āϚāĻŋāϤ āĻšāϝāĻŧ⧇āϛ⧇āĨ¤

āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ: āϞāĻŋāĻ–āĻŋāϤ āϰāĻŋāĻĒā§‹āĻ°ā§āϟ āĻĨ⧇āϕ⧇ āĻāχ āϰ⧋āĻ— āύāĻŋāĻ°ā§āĻŖāϝāĻŧ āϝāĻĨ⧇āĻˇā§āϟ āύāĻŋāĻ°ā§āĻ­āϰāϝ⧋āĻ—ā§āϝāĨ¤ āϤāĻŦ⧇ āĻļāĻŋāĻļ⧁āϟāĻŋāϰ āωāĻĒāϏāĻ°ā§āĻ—, āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻž āĻāĻŦāĻ‚ āĻĒā§āϰāϝāĻŧā§‹āϜāύ āĻšāϞ⧇ āĻ¨ā§āϝāĻžāϏāĻžāϞ āĻāĻ¨ā§āĻĄā§‹āĻ¸ā§āĻ•āĻĒāĻŋ āĻ›āĻžāĻĄāĻŧāĻž āĻĒā§āϰāĻ•ā§ƒāϤ āĻļā§āĻŦāĻžāϏāύāĻžāϞāĻŋāϰ āĻŦāĻžāϧāĻžāϰ āϤ⧀āĻŦā§āϰāϤāĻž, āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ•āĻžāϰāĻŖ āĻ•āĻŋāĻ‚āĻŦāĻž āĻ…āĻĒāĻžāϰ⧇āĻļāύ⧇āϰ āĻĒā§āϰāϝāĻŧā§‹āϜāύ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤


ā§§. REPORT NO. 1 — RADIOLOGY WRITTEN REPORT

🔴 Red Box Marked Report

āĻŽā§‚āϞ āϰāĻŋāĻĒā§‹āĻ°ā§āĻŸā§‡āϰ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āϞāĻžāχāύāϗ⧁āϞ⧋ āϞāĻžāϞ āĻŦāĻ•ā§āϏ āĻĻāĻŋāϝāĻŧ⧇ āϚāĻŋāĻšā§āύāĻŋāϤ āĻ•āϰ⧇āĻ›āĻŋāĨ¤ āĻĒā§āϰāϤāĻŋāϟāĻŋ āĻŦāĻ•ā§āϏ⧇āϰ āύāĻŽā§āĻŦāϰ āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āĻĒāĻžāĻļ⧇ āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ āĻĻ⧇āĻ“āϝāĻŧāĻž āĻšāϝāĻŧ⧇āϛ⧇āĨ¤

📷 Report No. 1 — Red Box Marked Image with Bangla Clinical Meaning

āϰāĻŋāĻĒā§‹āĻ°ā§āĻŸā§‡āϰ āĻĒā§āϰāϤāĻŋāϟāĻŋ āϞāĻžāχāύ⧇āϰ Clinical Interpretation

Original English ReportāĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ āĻ“ Clinical Significance
Digital X-ray of Nasopharynx, Lateral ViewāύāĻžāϕ⧇āϰ āĻĒ⧇āĻ›āύ⧇āϰ āĻ…āĻ‚āĻļ⧇āϰ āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĻāĻŋāϕ⧇āϰ āĻāĻ•ā§āϏ-āϰ⧇āĨ¤
🔴 Soft tissue swelling is seen in posterior wall nasopharynx.āύāĻžāϏ⧋āĻĢā§āϝāĻžāϰāĻŋāĻ‚āĻ•ā§āϏ⧇āϰ āĻĒ⧇āĻ›āύ⧇āϰ āĻĻ⧇āϝāĻŧāĻžāϞ⧇ āύāϰāĻŽ āϟāĻŋāĻ¸ā§āϝ⧁āϰ āĻŦ⧃āĻĻā§āϧāĻŋ āĻŦāĻž āĻĢā§‹āϞāĻžāĻ­āĻžāĻŦ āĻĻ⧇āĻ–āĻž āϝāĻžāĻšā§āϛ⧇āĨ¤ āĻāϟāĻŋ āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ āĻŦāĻĄāĻŧ āĻšāĻ“āϝāĻŧāĻžāϰ āϏāĻ™ā§āϗ⧇ āϏāĻžāĻŽāĻžā§āϜāĻ¸ā§āϝāĻĒā§‚āĻ°ā§āĻŖāĨ¤
🔴 Nasopharyngeal air column is mild to moderately compressed.āύāĻžāϕ⧇āϰ āĻĒ⧇āĻ›āύ⧇āϰ āĻŦāĻžāϝāĻŧ⧁ āϚāϞāĻžāϚāϞ⧇āϰ āĻĒāĻĨ āĻŽā§ƒāĻĻ⧁ āĻĨ⧇āϕ⧇ āĻŽāĻžāĻāĻžāϰāĻŋ āĻŽāĻžāĻ¤ā§āϰāĻžāϝāĻŧ āϏāĻ‚āϕ⧁āϚāĻŋāϤ āĻšāϝāĻŧ⧇āϛ⧇āĨ¤
Cervical spine appears normal.āĻ—āϞāĻžāϰ āĻŽā§‡āϰ⧁āĻĻāĻŖā§āĻĄā§‡āϰ āĻĻ⧃āĻļā§āϝāĻŽāĻžāύ āĻ…āĻ‚āĻļ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻŦāϞ⧇ āϰāĻŋāĻĒā§‹āĻ°ā§āϟ āĻ•āϰāĻž āĻšāϝāĻŧ⧇āϛ⧇āĨ¤
🔴 IMPRESSION: Mild to moderate adenoid hypertrophy.āϰ⧇āĻĄāĻŋāĻ“āϞāϜāĻŋāĻ¸ā§āĻŸā§‡āϰ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ: āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ āĻŽā§ƒāĻĻ⧁ āĻĨ⧇āϕ⧇ āĻŽāĻžāĻāĻžāϰāĻŋ āĻŽāĻžāĻ¤ā§āϰāĻžāϝāĻŧ āĻŦāĻĄāĻŧ āĻšāϝāĻŧ⧇āϛ⧇āĨ¤

đŸ”Ŧ Abnormal Findings

Abnormality 1: Adenoid Enlargement

āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ āĻšāϞ⧋ Nasopharynx-āĻāϰ āωāĻĒāϰ⧇āϰ āĻ“ āĻĒ⧇āĻ›āύ⧇āϰ āĻ…āĻ‚āĻļ⧇ āĻ…āĻŦāĻ¸ā§āĻĨāĻŋāϤ lymphoid tissue, āϝāĻž āĻļāĻŋāĻļ⧁āϰ āϰ⧋āĻ—āĻĒā§āϰāϤāĻŋāϰ⧋āϧ āĻŦā§āϝāĻŦāĻ¸ā§āĻĨāĻžāϰ āĻ…āĻ‚āĻļāĨ¤

āĻāχ āĻļāĻŋāĻļ⧁āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻāϟāĻŋ āĻŦāĻĄāĻŧ āĻšāĻ“āϝāĻŧāĻžāϰ āĻĒā§āϰāĻŽāĻžāĻŖ āĻĒāĻžāĻ“āϝāĻŧāĻž āϗ⧇āϛ⧇āĨ¤

Abnormality 2: Nasopharyngeal Airway Narrowing

āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ āĻŦāĻĄāĻŧ āĻšāĻ“āϝāĻŧāĻžāϰ āĻ•āĻžāϰāϪ⧇ āύāĻžāϕ⧇āϰ āĻĒ⧇āĻ›āύ⧇āϰ āĻŦāĻžāϝāĻŧ⧁āĻĒāĻĨ āϏāĻ‚āϕ⧁āϚāĻŋāϤ āĻšāϝāĻŧ⧇āϛ⧇āĨ¤

āĻāϰ āĻĢāϞ⧇ āύāĻžāĻ• āĻŦāĻ¨ā§āϧ āĻĨāĻžāĻ•āĻž, āĻŽā§āĻ– āĻĻāĻŋāϝāĻŧ⧇ āĻļā§āĻŦāĻžāϏ āύ⧇āĻ“āϝāĻŧāĻž āĻŦāĻž āύāĻžāĻ• āĻĄāĻžāĻ•āĻžāϰ āĻŽāϤ⧋ āωāĻĒāϏāĻ°ā§āĻ— āĻĻ⧇āĻ–āĻž āĻĻāĻŋāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

āϤāĻŦ⧇ X-ray-āĻ āĻŦāĻžāϝāĻŧ⧁āĻĒāĻĨ āϏāĻ‚āϕ⧁āϚāĻŋāϤ āĻĒāĻžāĻ“āϝāĻŧāĻž āĻŽāĻžāύ⧇āχ āĻļāĻŋāĻļ⧁āϟāĻŋāϰ Obstructive Sleep Apnea āϰāϝāĻŧ⧇āϛ⧇, āĻāĻŽāύ āύāϝāĻŧāĨ¤


⧍. REPORT NO. 2 — LATERAL NASOPHARYNGEAL X-RAY FILM

🔴 Red Box Marked X-ray

📷 Report No. 2 — X-ray Film Marked with Red Boxes and Bangla Explanation

X-ray-āĻāϰ āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

🔴 Box 1: Nasopharyngeal Region

āĻāχ āĻŦāĻ•ā§āϏ⧇ āύāĻžāϕ⧇āϰ āĻĒ⧇āĻ›āύ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ āĻ“ āĻŦāĻžāϝāĻŧ⧁āĻĒāĻĨ⧇āϰ āĻļāĻžāϰ⧀āϰāĻ¸ā§āĻĨāĻžāύāĻŋāĻ• āĻ…āĻžā§āϚāϞ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻ•āϰāĻž āĻšāϝāĻŧ⧇āϛ⧇āĨ¤

āĻāϟāĻŋ āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄā§‡āϰ āύāĻŋāĻ°ā§āϭ⧁āϞ āϏ⧀āĻŽāĻžāύāĻž āύāϝāĻŧāĨ¤

🔴 Box 2: Image Glare

āĻāχ āĻ…āĻ‚āĻļ⧇ āφāϞ⧋ āĻĒā§āϰāϤāĻŋāĻĢāϞāĻŋāϤ āĻšāϝāĻŧ⧇āϛ⧇āĨ¤ āĻāϟāĻŋ āϕ⧋āύ⧋ āϰ⧋āϗ⧇āϰ āϞāĻ•ā§āώāĻŖ āύāϝāĻŧ, āϤāĻŦ⧇ āĻ›āĻŦāĻŋāϰ āĻ•āĻŋāϛ⧁ āĻ…āĻ‚āĻļ āĻ…āĻ¸ā§āĻĒāĻˇā§āϟ āĻ•āϰ⧇āϛ⧇āĨ¤

Clinical Interpretation

āĻĻā§āĻŦāĻŋāϤ⧀āϝāĻŧ āĻ›āĻŦāĻŋāϟāĻŋ āĻŽā§‹āĻŦāĻžāχāϞ⧇ āϤ⧋āϞāĻž X-ray film-āĻāϰ āĻ›āĻŦāĻŋāĨ¤ āĻāϤ⧇ āφāϞ⧋āϰ āĻĒā§āϰāϤāĻŋāĻĢāϞāύ āĻ“ āĻ›āĻŦāĻŋāϰ āĻŽāĻžāύ⧇āϰ āϏ⧀āĻŽāĻžāĻŦāĻĻā§āϧāϤāĻž āϰāϝāĻŧ⧇āϛ⧇āĨ¤

āϤāĻžāχ āĻāχ āĻ›āĻŦāĻŋ āĻĨ⧇āϕ⧇ āĻ¸ā§āĻŦāĻžāϧ⧀āύāĻ­āĻžāĻŦ⧇ āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄā§‡āϰ āύāĻŋāĻ°ā§āϭ⧁āϞ āĻŽāĻžāĻĒ, obstruction percentage āĻ…āĻĨāĻŦāĻž endoscopic grade āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāĻž āϝāĻžāĻšā§āϛ⧇ āύāĻžāĨ¤

āĻĒā§āϰāĻĨāĻŽ āϰāĻŋāĻĒā§‹āĻ°ā§āĻŸā§‡ āϝ⧇ mild-to-moderate adenoid hypertrophy āωāĻ˛ā§āϞ⧇āĻ– āĻ•āϰāĻž āĻšāϝāĻŧ⧇āϛ⧇, āϏ⧇āϟāĻŋāχ āĻŦāĻ°ā§āϤāĻŽāĻžāύ⧇ āϏāĻŦāĻšā§‡āϝāĻŧ⧇ āύāĻŋāĻ°ā§āĻ­āϰāϝ⧋āĻ—ā§āϝ radiological findingāĨ¤


ā§Š. FINAL DIAGNOSIS — PRESCRIPTION-āĻ āϕ⧀ āϞāĻŋāĻ–āĻŦ⧇āύ?

✅ Radiological Diagnosis

Adenoid Hypertrophy (Mild to Moderate)

ICD-10-CM: J35.2 — Hypertrophy of Adenoids

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϞ⧇āĻ–āĻž āϝāĻžāϝāĻŧ:

Provisional Dx: Adenoid Hypertrophy with Radiographic Nasopharyngeal Airway Narrowing.

āĻŦāĻžāĻ‚āϞāĻž:

āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ āĻŦāĻĄāĻŧ āĻšāϝāĻŧ⧇ āύāĻžāϕ⧇āϰ āĻĒ⧇āĻ›āύ⧇āϰ āĻŦāĻžāϝāĻŧ⧁āĻĒāĻĨ āϏāĻ‚āϕ⧁āϚāĻŋāϤ āĻšāĻ“āϝāĻŧāĻžāĨ¤

Diagnostic Confidence

AssessmentConfidence
āϰāĻŋāĻĒā§‹āĻ°ā§āĻŸā§‡ Mild to Moderate Adenoid Hypertrophy āωāĻ˛ā§āϞ⧇āĻ– āϰāϝāĻŧ⧇āϛ⧇0.99
Radiological diagnosis āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ āĻšāĻžāχāĻĒāĻžāϰāĻŸā§āϰāĻĢāĻŋāϰ āϏāĻ™ā§āϗ⧇ āϏāĻžāĻŽāĻžā§āϜāĻ¸ā§āϝāĻĒā§‚āĻ°ā§āĻŖ0.95
āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄā§‡āϰ āĻ•āĻžāϰāϪ⧇ āĻ•āĻŋāϛ⧁ āĻŽāĻžāĻ¤ā§āϰāĻžāϝāĻŧ āĻŦāĻžāϝāĻŧ⧁āĻĒāĻĨ āϏāĻ‚āϕ⧁āϚāĻŋāϤ āĻšāϝāĻŧ⧇āϛ⧇0.90
āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ•āĻžāϰāĻŖ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻŦāĻž āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāĻž āϝāĻžāϝāĻŧāύāĻŋ
Obstructive Sleep Apnea āϰāϝāĻŧ⧇āϛ⧇āĻŦāĻ°ā§āϤāĻŽāĻžāύ⧇ āĻĒā§āϰāĻŽāĻžāĻŖ āύ⧇āχ
āĻ…āĻ¸ā§āĻ¤ā§āϰ⧋āĻĒāϚāĻžāϰ āĻĒā§āϰāϝāĻŧā§‹āϜāύāĻŦāĻ°ā§āϤāĻŽāĻžāύ⧇ āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāĻž āϝāĻžāϝāĻŧāύāĻŋ

ā§Ē. ETIOLOGY / PATHOPHYSIOLOGY

āϕ⧇āύ Adenoid Hypertrophy āĻšāϝāĻŧ?

āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ āĻŦāĻĄāĻŧ āĻšāĻ“āϝāĻŧāĻžāϰ āĻĒ⧇āĻ›āύ⧇ āĻāĻ•āĻžāϧāĻŋāĻ• āĻ•āĻžāϰāĻŖ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Possible CausesClinical Explanation
Recurrent upper respiratory infectionsāĻŦāĻžāϰāĻŦāĻžāϰ āĻ­āĻžāχāϰāĻžāϞ āĻŦāĻž āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻļā§āĻŦāĻžāϏāϤāĻ¨ā§āĻ¤ā§āϰ⧇āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āĻĢāϞ⧇ lymphoid tissue āĻŦāĻĄāĻŧ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
Chronic inflammationāĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžāϝāĻŧā§€ āĻĒā§āϰāĻĻāĻžāĻšā§‡ āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ āϟāĻŋāĻ¸ā§āϝ⧁āϰ āĻŦ⧃āĻĻā§āϧāĻŋ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
Allergic rhinitisāĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āϏāĻšāĻžāĻŦāĻ¸ā§āĻĨāĻžāύ āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇ āĻāĻŦāĻ‚ āύāĻžāĻ• āĻŦāĻ¨ā§āϧ āĻĨāĻžāĻ•āĻžāϰ āϏāĻŽāĻ¸ā§āϝāĻž āĻŦāĻžāĻĄāĻŧāĻžāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
Physiological lymphoid enlargementāĻļāĻŋāĻļ⧁āϰ āĻŦāϝāĻŧāϏ⧇ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āϰ⧋āĻ—āĻĒā§āϰāϤāĻŋāϰ⧋āϧ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āϰāĻŽā§‡āϰ āĻ…āĻ‚āĻļ āĻšāĻŋāϏ⧇āĻŦ⧇ āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ āϤ⧁āϞāύāĻžāĻŽā§‚āϞāĻ• āĻŦāĻĄāĻŧ āĻĨāĻžāϕ⧇āĨ¤
Repeated antigenic stimulationāĻœā§€āĻŦāĻžāϪ⧁ āĻ“ āĻĒāϰāĻŋāĻŦ⧇āĻļāĻ—āϤ āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻœā§‡āύ⧇āϰ āϏāĻ‚āĻ¸ā§āĻĒāĻ°ā§āĻļ⧇ lymphoid tissue āĻŦ⧃āĻĻā§āϧāĻŋ āĻĒ⧇āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

āĻāχ āϰ⧋āĻ—ā§€āϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ•āĻžāϰāĻŖ āϰāĻŋāĻĒā§‹āĻ°ā§āϟ āĻĨ⧇āϕ⧇ āϜāĻžāύāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ, chronic adenoiditis āĻ…āĻĨāĻŦāĻž recurrent infection āφāϛ⧇ āĻ•āĻŋ āύāĻž, āϤāĻž āχāϤāĻŋāĻšāĻžāϏ āĻ“ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰ⧇ āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ āĻŦāĻĄāĻŧ āĻšāϞ⧇ āύāĻžāϕ⧇āϰ āĻĒ⧇āĻ›āύ⧇āϰ āĻŦāĻžāϝāĻŧ⧁āĻĒāĻĨ⧇ āĻŦāĻžāϧāĻž āϤ⧈āϰāĻŋ āĻšāϤ⧇ āĻĒāĻžāϰ⧇ āĻāĻŦāĻ‚ Eustachian tube-āĻāϰ āĻ•āĻžāĻ°ā§āϝāĻ•āĻžāϰāĻŋāϤāĻžāĻ“ āĻŦāĻŋāĻ˜ā§āύāĻŋāϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āĻĢāϞ⧇ āĻ•āĻŋāϛ⧁ āĻļāĻŋāĻļ⧁āϰ middle-ear effusion āĻ“ conductive hearing loss āĻĻ⧇āĻ–āĻž āĻĻ⧇āϝāĻŧāĨ¤


ā§Ģ. CLINICAL FEATURES — āϰ⧋āĻ—ā§€āϰ āϕ⧀ āϕ⧀ āωāĻĒāϏāĻ°ā§āĻ— āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇?

āĻāχ āĻļāĻŋāĻļ⧁āϰ āĻŦāĻ°ā§āϤāĻŽāĻžāύ āωāĻĒāϏāĻ°ā§āĻ— āĻĻ⧇āĻ“āϝāĻŧāĻž āĻšāϝāĻŧāύāĻŋāĨ¤ āύāĻŋāĻšā§‡āϰ āϞāĻ•ā§āώāĻŖāϗ⧁āϞ⧋ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ•āϕ⧇ āϜāĻŋāĻœā§āĻžāĻžāϏāĻž āĻ“ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Clinical FeatureāĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ
Nasal obstructionāύāĻžāĻ• āĻŦāĻ¨ā§āϧ āĻĨāĻžāĻ•āĻž
Mouth breathingāĻŽā§āĻ– āĻĻāĻŋāϝāĻŧ⧇ āĻļā§āĻŦāĻžāϏ āύ⧇āĻ“āϝāĻŧāĻž
SnoringāϘ⧁āĻŽā§‡āϰ āϏāĻŽāϝāĻŧ āύāĻžāĻ• āĻĄāĻžāĻ•āĻž
Sleep-disordered breathingāϘ⧁āĻŽā§‡āϰ āϏāĻŽāϝāĻŧ āĻ…āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻļā§āĻŦāĻžāϏāĻĒā§āϰāĻļā§āĻŦāĻžāϏ
Witnessed apneaāϘ⧁āĻŽā§‡āϰ āϏāĻŽāϝāĻŧ āĻļā§āĻŦāĻžāϏ āĻŦāĻ¨ā§āϧ āĻšāϝāĻŧ⧇ āϝāĻžāĻ“āϝāĻŧāĻžāϰ āϘāϟāύāĻž
Recurrent rhinorrheaāĻŦāĻžāϰāĻŦāĻžāϰ āύāĻžāĻ• āĻĻāĻŋāϝāĻŧ⧇ āĻĒāĻžāύāĻŋ āĻŦāĻž āϏāĻ°ā§āĻĻāĻŋ āĻĒāĻĄāĻŧāĻž
Hyponasal voiceāύāĻžāĻ• āĻŦāĻ¨ā§āϧ āĻĨāĻžāĻ•āϞ⧇ āϝ⧇āĻŽāύ āĻ•āĻĨāĻž āĻļā§‹āύāĻžāϝāĻŧ
Hearing impairmentāĻ•āĻžāύ⧇ āĻ•āĻŽ āĻļā§‹āύāĻž
Recurrent otitis mediaāĻŦāĻžāϰāĻŦāĻžāϰ āĻŽāĻ§ā§āϝāĻ•āĻ°ā§āϪ⧇āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ
Daytime tiredness/poor attentionāĻĻāĻŋāύ⧇āϰ āĻŦ⧇āϞāĻžāϝāĻŧ āĻ•ā§āϞāĻžāĻ¨ā§āϤāĻŋ āĻŦāĻž āĻŽāύ⧋āϝ⧋āĻ— āĻ•āĻŽā§‡ āϝāĻžāĻ“āϝāĻŧāĻž

āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ āĻŦāĻĄāĻŧ āĻĨāĻžāĻ•āϞ⧇āĻ“ āϏāĻŦ āĻļāĻŋāĻļ⧁āϰ āĻāϏāĻŦ āωāĻĒāϏāĻ°ā§āĻ— āĻšāϝāĻŧ āύāĻžāĨ¤


ā§Ŧ. ADDITIONAL INVESTIGATIONS

āĻāĻ–āύ āϕ⧋āύ āĻĒāϰ⧀āĻ•ā§āώāĻž āϏāĻŦāĻšā§‡āϝāĻŧ⧇ āĻĒā§āϰāϝāĻŧā§‹āϜāύ?

InvestigationClinical Indication
Flexible NasopharyngoscopyāĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄā§‡āϰ āφāĻ•āĻžāϰ, āĻ…āĻŦāĻ¸ā§āĻĨāĻžāύ āĻāĻŦāĻ‚ āĻŦāĻžāϝāĻŧ⧁āĻĒāĻĨ⧇ āĻŦāĻžāϧāĻžāϰ āĻĒāϰāĻŋāĻŽāĻžāĻŖ āϏāϰāĻžāϏāϰāĻŋ āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻ•āϰāĻžāĨ¤
Anterior RhinoscopyāύāĻžāϕ⧇āϰ āϭ⧇āϤāϰ⧇ allergic rhinitis, turbinate hypertrophy āĻŦāĻž āĻ…āĻ¨ā§āϝ āĻŦāĻžāϧāĻž āφāϛ⧇ āĻ•āĻŋ āύāĻž āĻĻ⧇āĻ–āĻžāĨ¤
OtoscopyāĻŽāĻ§ā§āϝāĻ•āĻ°ā§āϪ⧇ āϤāϰāϞ āϜāĻŽā§‡āϛ⧇ āĻ•āĻŋ āύāĻž āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰāĻžāĨ¤
TympanometryEustachian tube dysfunction āĻŦāĻž middle-ear effusion āϏāĻ¨ā§āĻĻ⧇āĻš āĻšāϞ⧇āĨ¤
Pure Tone AudiometryāĻļā§āϰāĻŦāĻŖāĻļāĻ•ā§āϤāĻŋ āĻ•āĻŽā§‡ āϝāĻžāĻ“āϝāĻŧāĻžāϰ āĻ…āĻ­āĻŋāϝ⧋āĻ— āĻĨāĻžāĻ•āϞ⧇ āĻŦāϝāĻŧāϏ⧋āĻĒāϝ⧋āĻ—ā§€ hearing assessmentāĨ¤
PolysomnographyāύāĻŋāϝāĻŧāĻŽāĻŋāϤ āύāĻžāĻ• āĻĄāĻžāĻ•āĻž, āϘ⧁āĻŽā§‡āϰ āĻŽāĻ§ā§āϝ⧇ āĻļā§āĻŦāĻžāϏ āĻŦāĻ¨ā§āϧ āĻšāĻ“āϝāĻŧāĻž āĻŦāĻž OSA-āĻāϰ āϞāĻ•ā§āώāĻŖ āĻĨāĻžāĻ•āϞ⧇āĨ¤
Allergy TestingāχāϤāĻŋāĻšāĻžāϏ⧇ allergic rhinitis-āĻāϰ āĻļāĻ•ā§āϤ āĻĒā§āϰāĻŽāĻžāĻŖ āĻĨāĻžāĻ•āϞ⧇ āĻāĻŦāĻ‚ āĻĢāϞ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇ āĻāĻŽāύ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇āĨ¤

āϏāĻŦāĻšā§‡āϝāĻŧ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻĒāϰ⧀āĻ•ā§āώāĻž

ENT examination Âą Flexible Nasopharyngoscopy

āĻ¨ā§āϝāĻžāϏ⧋āĻāĻ¨ā§āĻĄā§‹āĻ¸ā§āĻ•āĻĒāĻŋ āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ āϏāϰāĻžāϏāϰāĻŋ āĻĻ⧇āĻ–āϤ⧇ āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝ āϰ⧋āĻ— āĻĨ⧇āϕ⧇ āĻĒ⧃āĻĨāĻ• āĻ•āϰāϤ⧇ āϏāĻžāĻšāĻžāĻ¯ā§āϝ āĻ•āϰ⧇āĨ¤

āϤāĻŦ⧇ āϏāĻŦ āĻļāĻŋāĻļ⧁āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻāϟāĻŋ āĻŦāĻžāĻ§ā§āϝāϤāĻžāĻŽā§‚āϞāĻ• āύāϝāĻŧ; āĻļāĻŋāĻļ⧁āϰ āϏāĻšāϝ⧋āĻ—āĻŋāϤāĻž, āωāĻĒāϏāĻ°ā§āĻ— āĻāĻŦāĻ‚ ENT āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻ­āĻŋāĻ¤ā§āϤāĻŋāϤ⧇ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ āύ⧇āĻ“āϝāĻŧāĻž āĻšāϝāĻŧāĨ¤

āĻāχ āϰāĻŋāĻĒā§‹āĻ°ā§āϟ āĻĒāĻžāĻ“āϝāĻŧāĻžāϰ āĻĒāϰ āύāĻŋāϝāĻŧāĻŽāĻŋāϤāĻ­āĻžāĻŦ⧇ āφāĻŦāĻžāϰ X-ray āĻŦāĻž CT scan āĻ•āϰāĻžāϰ āĻĒā§āϰāϝāĻŧā§‹āϜāύ āύ⧇āχāĨ¤ āĻŦāĻŋāĻļ⧇āώ āϕ⧋āύ⧋ āϏāĻ¨ā§āĻĻ⧇āĻš āĻĨāĻžāĻ•āϞ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ imaging āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāĻŦ⧇āύāĨ¤


ā§­. DIFFERENTIAL DIAGNOSIS

āϝāĻĻāĻŋāĻ“ āϰāĻŋāĻĒā§‹āĻ°ā§āϟ āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ āĻšāĻžāχāĻĒāĻžāϰāĻŸā§āϰāĻĢāĻŋāϰ āĻĒāĻ•ā§āώ⧇, āύāĻžāĻ• āĻŦāĻ¨ā§āϧ āĻĨāĻžāĻ•āĻžāϰ āĻ…āĻ¨ā§āϝ āĻ•āĻžāϰāĻŖāϗ⧁āϞ⧋āĻ“ āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Differential DiagnosisāĻ•āĻ–āύ āϏāĻ¨ā§āĻĻ⧇āĻš āĻ•āϰāĻŦ⧇āύ?
Allergic rhinitisāĻšāĻžāρāϚāĻŋ, āύāĻžāĻ• āϚ⧁āϞāĻ•āĻžāύ⧋, āĻ¸ā§āĻŦāĻšā§āĻ› āϏāĻ°ā§āĻĻāĻŋ
Chronic adenoiditisāĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžāϝāĻŧā§€ āĻŦāĻž āĻĒ⧁āύāϰāĻžāĻŦ⧃āĻ¤ā§āϤ āύāĻžāϕ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻ“ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϞāĻ•ā§āώāĻŖ
Inferior turbinate hypertrophyāύāĻžāϕ⧇āϰ āϭ⧇āϤāϰ⧇āϰ turbinate āĻŦāĻĄāĻŧ āĻĒāĻžāĻ“āϝāĻŧāĻž
Tonsillar hypertrophyāĻŽā§āĻ–āĻ—āĻšā§āĻŦāϰ⧇ āĻŦāĻĄāĻŧ tonsil āĻāĻŦāĻ‚ āϘ⧁āĻŽā§‡āϰ āĻļā§āĻŦāĻžāϏāĻĒā§āϰāĻļā§āĻŦāĻžāϏ⧇āϰ āϏāĻŽāĻ¸ā§āϝāĻž
Chronic rhinosinusitisāĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžāϝāĻŧā§€ āύāĻžāĻ• āĻŦāĻ¨ā§āϧ, āϏāĻ°ā§āĻĻāĻŋ, āĻ•āĻžāĻļāĻŋ
Choanal stenosisāύāĻžāϕ⧇āϰ āĻĒ⧇āĻ›āύ⧇āϰ āĻĒāĻĨ⧇āϰ āĻ—āĻ āύāĻ—āϤ āϏāĻ‚āϕ⧀āĻ°ā§āĻŖāϤāĻž
Nasopharyngeal massāĻ…āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻāĻ•āĻĒāĻžāĻļ⧇āϰ āĻŦāĻžāϧāĻž, āϰāĻ•ā§āϤāĻĒāĻžāϤ āĻŦāĻž āĻ…āĻ¨ā§āϝ āϏāϤāĻ°ā§āĻ•āϤāĻžāĻŽā§‚āϞāĻ• āϞāĻ•ā§āώāĻŖ

āĻāχ āĻŦāϝāĻŧāϏ⧇ adenoid hypertrophy āĻāĻ•āϟāĻŋ āϝ⧁āĻ•ā§āϤāĻŋāϏāĻ‚āĻ—āϤ āĻĒā§āϰāϧāĻžāύ diagnosisāĨ¤ āϤāĻŦ⧇ āĻ…āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āωāĻĒāϏāĻ°ā§āĻ— āĻĨāĻžāĻ•āϞ⧇ āĻ…āĻ¨ā§āϝ āĻ•āĻžāϰāĻŖ āĻŦāĻžāĻĻ āĻĻ⧇āĻ“āϝāĻŧāĻž āϜāϰ⧁āϰāĻŋāĨ¤


ā§Ž. TREATMENT PLAN — Guideline-Based Management

A. Conservative Management

āĻļāĻŋāĻļ⧁āϰ āωāĻĒāϏāĻ°ā§āĻ— āϝāĻĻāĻŋ āĻŽā§ƒāĻĻ⧁ āĻšāϝāĻŧ āĻāĻŦāĻ‚ āωāĻ˛ā§āϞ⧇āĻ–āϝ⧋āĻ—ā§āϝ sleep apnea, hearing loss āĻ…āĻĨāĻŦāĻž persistent ear disease āύāĻž āĻĨāĻžāϕ⧇, āϤāĻžāĻšāϞ⧇ āĻĒā§āϰāĻĨāĻŽā§‡ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϤāĻ¤ā§āĻ¤ā§āĻŦāĻžāĻŦāϧāĻžāύ⧇ conservative management āωāĻĒāϝ⧁āĻ•ā§āϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Normal saline nasal spray: āύāĻžāĻ• āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰ āĻ“ āϏāĻ°ā§āĻĻāĻŋ/āϜāĻŽā§‡ āĻĨāĻžāĻ•āĻž secretion āĻ•āĻŽāĻžāϤ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āϝāĻžāϝāĻŧāĨ¤ āĻāϟāĻŋ āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ āϟāĻŋāĻ¸ā§āϝ⧁ āύāĻŋāĻļā§āϚāĻŋāϤāĻ­āĻžāĻŦ⧇ āϛ⧋āϟ āĻ•āϰ⧇ āĻĻ⧇āϝāĻŧ āύāĻžāĨ¤

Allergic rhinitis āĻĨāĻžāĻ•āϞ⧇: Intranasal corticosteroid āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāĻž āϝāĻžāϝāĻŧāĨ¤

āωāĻĻāĻžāĻšāϰāĻŖ āĻšāĻŋāϏ⧇āĻŦ⧇, ā§¨â€“ā§§ā§§ āĻŦāĻ›āϰ āĻŦāϝāĻŧāϏ⧀ āĻļāĻŋāĻļ⧁āϰ allergic rhinitis-āĻāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ mometasone furoate nasal spray 50 microgram āĻĒā§āϰāϤāĻŋ āύāĻžāϏāĻžāϰāĻ¨ā§āĻ§ā§āϰ⧇ āĻāĻ• āĻ¸ā§āĻĒā§āϰ⧇ āĻ•āϰ⧇ āĻĻ⧈āύāĻŋāĻ• āĻāĻ•āĻŦāĻžāϰ āĻāĻ•āϟāĻŋ āĻ…āύ⧁āĻŽā§‹āĻĻāĻŋāϤ dosing regimenāĨ¤ āϤāĻŦ⧇ āĻāχ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āĻ“āώ⧁āϧ āĻļ⧁āϰ⧁ āĻ•āϰāĻžāϰ āφāϗ⧇ history, nasal examination āĻ“ contraindications āϝāĻžāϚāĻžāχ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤ āĻāχ āĻĄā§‹āϜāϟāĻŋ allergic rhinitis-āĻāϰ āϜāĻ¨ā§āϝ, āϕ⧇āĻŦāϞ X-ray-āĻ āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ āĻŦāĻĄāĻŧ āĻĻ⧇āĻ–āĻžāϰ āϜāĻ¨ā§āϝ āĻ¸ā§āĻŦāϝāĻŧāĻ‚āĻ•ā§āϰāĻŋāϝāĻŧ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āύāϝāĻŧāĨ¤

āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āύāϤ⧁āύ āĻ—āĻŦ⧇āώāĻŖāĻž

⧍ā§Ļ⧍ā§Ŧ āϏāĻžāϞ⧇ JAMA Pediatrics-āĻ āĻĒā§āϰāĻ•āĻžāĻļāĻŋāϤ MIST+ randomized trial-āĻ āĻļāĻŋāĻļ⧁āĻĻ⧇āϰ obstructive sleep-disordered breathing-āĻāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ saline āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻĒāϰ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ intranasal mometasone āĻĻāĻŋāϝāĻŧ⧇ saline-āĻāϰ āϤ⧁āϞāύāĻžāϝāĻŧ āωāĻ˛ā§āϞ⧇āĻ–āϝ⧋āĻ—ā§āϝ āĻŦāĻžāĻĄāĻŧāϤāĻŋ āωāĻĒāĻ•āĻžāϰ āĻĒāĻžāĻ“āϝāĻŧāĻž āϝāĻžāϝāĻŧāύāĻŋāĨ¤

āϤāĻžāχ intranasal steroid āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄā§‡āϰ āĻ•āĻžāϰāϪ⧇ āĻšāĻ“āϝāĻŧāĻž āϏāĻŦ breathing problem-āĻ āύāĻŋāĻļā§āϚāĻŋāϤāĻ­āĻžāĻŦ⧇ āĻ•āĻžāĻ°ā§āϝāĻ•āĻ°â€”āĻāĻŽāύ āĻĻāĻžāĻŦāĻŋ āĻ•āϰāĻž āĻ āĻŋāĻ• āύāϝāĻŧāĨ¤

āϝ⧇āϏāĻŦ āĻ“āώ⧁āϧ āύāĻŋāϝāĻŧāĻŽāĻŋāϤ āĻĒā§āϰāϝāĻŧā§‹āϜāύ āύ⧇āχ

āĻļ⧁āϧ⧁ adenoid hypertrophy āĻĨāĻžāĻ•āϞ⧇āχ systemic steroid, antibiotic āĻŦāĻž antihistamine āĻĻ⧇āĻ“āϝāĻŧāĻžāϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž āύ⧇āχāĨ¤

Antibiotic āĻĒā§āϰāϝāĻŧā§‹āϜāύ āĻšāϞ⧇ āϤāĻžāϰ āĻĒ⧃āĻĨāĻ• infectious indication āĻĨāĻžāĻ•āϤ⧇ āĻšāĻŦ⧇āĨ¤ Antihistamine āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āϝ⧇āϤ⧇ āĻĒāĻžāϰ⧇ āϏāĻšāĻžāĻŦāĻ¸ā§āĻĨāĻžāύāĻ•āĻžāϰ⧀ allergic rhinitis-āĻāϰ āωāĻĒāϏāĻ°ā§āϗ⧇āϰ āϜāĻ¨ā§āϝāĨ¤


B. Surgical Management

Adenoidectomy āĻ•āĻ–āύ āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāĻŦ⧇āύ?

Adenoidectomy āĻšāϞ⧋ āĻ…āĻ¸ā§āĻ¤ā§āϰ⧋āĻĒāϚāĻžāϰ⧇āϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡ āĻŦāĻĄāĻŧ āĻšāĻ“āϝāĻŧāĻž āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ āϟāĻŋāĻ¸ā§āϝ⧁ āĻ…āĻĒāϏāĻžāϰāĻŖāĨ¤

AAO-HNS clinical indicators āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ surgical indications-āĻāϰ āĻŽāĻ§ā§āϝ⧇ āϰāϝāĻŧ⧇āϛ⧇:

  • āĻ…āĻ¨ā§āϤāϤ āϤāĻŋāύ āĻŽāĻžāϏ āϧāϰ⧇ nasal obstruction-āĻāϰ āϏāĻ™ā§āϗ⧇ sleep disturbanceāĨ¤
  • Persistent otitis media with effusionāĨ¤
  • āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϝāĻŧ āύāĻž āĻ•āĻŽāĻž chronic/recurrent adenoiditisāĨ¤
  • āωāĻ˛ā§āϞ⧇āĻ–āϝ⧋āĻ—ā§āϝ hyponasal speechāĨ¤
  • āĻ…ā§āϝāĻžāĻĄāĻŋāύāϝāĻŧ⧇āĻĄ-āϏāĻŽā§āĻĒāĻ°ā§āĻ•āĻŋāϤ dental āĻŦāĻž facial growth disturbanceāĨ¤
  • āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ complicationsāĨ¤

āĻāχ āĻļāĻŋāĻļ⧁āϰ X-ray-āĻ Mild to Moderate Adenoid Hypertrophy āĻĨāĻžāĻ•āϞ⧇āχ Adenoidectomy āĻ•āϰāϤ⧇ āĻšāĻŦā§‡â€”āĻāĻŽāύ āύāϝāĻŧāĨ¤

āĻ…āĻĒāĻžāϰ⧇āĻļāύ⧇āϰ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ āĻŽā§‚āϞāϤ āωāĻĒāϏāĻ°ā§āĻ—, āĻ•āĻžāύ⧇āϰ āϏāĻŽāĻ¸ā§āϝāĻž, āϘ⧁āĻŽā§‡āϰ āĻļā§āĻŦāĻžāϏāĻĒā§āϰāĻļā§āĻŦāĻžāϏ, āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻāĻŦāĻ‚ conservative treatment-āĻāϰ āĻĢāϞāĻžāĻĢāϞ⧇āϰ āĻ“āĻĒāϰ āύāĻŋāĻ°ā§āĻ­āϰ āĻ•āϰāĻŦ⧇āĨ¤

āϝāĻĻāĻŋ confirmed obstructive sleep apnea-āĻāϰ āϏāĻ™ā§āϗ⧇ tonsillar hypertrophy-āĻ“ āĻĨāĻžāϕ⧇, āϤāĻžāĻšāϞ⧇ ENT specialist adenotonsillectomy āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇āύāĨ¤


⧝. DOCTOR’S ACTION PLAN — āĻāĻ–āύ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϕ⧀ āĻ•āϰāĻŦ⧇āύ?

āĻĒā§āϰāĻĨāĻŽ āĻ­āĻŋāϜāĻŋāĻŸā§‡: āĻļāĻŋāĻļ⧁āϰ nasal obstruction, mouth breathing, snoring, witnessed apnea, recurrent infection, hearing difficulty āĻ“ allergy-āĻāϰ āχāϤāĻŋāĻšāĻžāϏ āύāĻŋāϤ⧇ āĻšāĻŦ⧇āĨ¤

Clinical examination: āύāĻžāĻ•, tonsil, palate, oropharynx, lymph node āĻ“ āĻĻ⧁āχ āĻ•āĻžāύ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤ āĻŦāϝāĻŧāϏ āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ growth assessment-āĻ“ āĻĒā§āϰāĻžāϏāĻ™ā§āĻ—āĻŋāĻ•āĨ¤

āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āĻĒāĻĻāĻ•ā§āώ⧇āĻĒ: Pediatric ENT consultation āĻ•āϰ⧇ āĻĒā§āϰāϝāĻŧā§‹āϜāύ āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ flexible nasopharyngoscopy āĻāĻŦāĻ‚ ear assessment āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Mild symptoms āĻĨāĻžāĻ•āϞ⧇: Saline āĻ“ āĻĒā§āϰāϝāĻŧā§‹āϜāύ āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āϏāĻšāĻžāĻŦāĻ¸ā§āĻĨāĻžāύāĻ•āĻžāϰ⧀ allergic rhinitis-āĻāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻĻāĻŋāϝāĻŧ⧇ āĻĒ⧁āύāĻ°ā§āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύāĨ¤

Significant symptoms āĻĨāĻžāĻ•āϞ⧇: ENT assessment āĻāĻŦāĻ‚ āĻĒā§āϰāϝāĻŧā§‹āϜāύ āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ hearing test āĻŦāĻž sleep studyāĨ¤ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϝāĻŧ āωāĻ¨ā§āύāϤāĻŋ āύāĻž āĻšāϞ⧇ surgery-āĻāϰ āĻĒā§āϰāϝāĻŧā§‹āϜāύ āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύāĨ¤

āϜāϰ⧁āϰāĻŋ āϏāϤāĻ°ā§āĻ•āϤāĻž: āĻļā§āĻŦāĻžāϏ āύāĻŋāϤ⧇ āωāĻ˛ā§āϞ⧇āĻ–āϝ⧋āĻ—ā§āϝ āĻ•āĻˇā§āϟ, āĻ ā§‹āρāϟ āύ⧀āϞ āĻšāϝāĻŧ⧇ āϝāĻžāĻ“āϝāĻŧāĻž, āĻĻā§€āĻ°ā§āϘāĻ•ā§āώāĻŖ āĻļā§āĻŦāĻžāϏ āĻŦāĻ¨ā§āϧ āĻĨāĻžāĻ•āĻž, āĻ…āĻĨāĻŦāĻž āϘ⧁āĻŽā§‡āϰ āĻŽāĻ§ā§āϝ⧇ āϗ⧁āϰ⧁āϤāϰ āĻļā§āĻŦāĻžāϏāĻ•āĻˇā§āϟ āĻĨāĻžāĻ•āϞ⧇ āϜāϰ⧁āϰāĻŋ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤


ā§§ā§Ļ. REFERRAL — āϕ⧋āύ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻ•āĻžāϛ⧇ āĻĒāĻžāĻ āĻžāĻŦ⧇āύ?

✅ Recommended Specialist

Consultant ENT & Head-Neck Surgeon

āĻŦāĻŋāĻļ⧇āώāϤ āĻļāĻŋāĻļ⧁āĻĻ⧇āϰ ENT āϰ⧋āϗ⧇āϰ āĻ…āĻ­āĻŋāĻœā§āĻžāϤāĻž āφāϛ⧇ āĻāĻŽāύ specialistāĨ¤

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ referral note āĻāĻ­āĻžāĻŦ⧇ āϞ⧇āĻ–āĻž āϝāĻžāϝāĻŧ: Clinical ENT Referral Note

To: Consultant ENT & Head-Neck Surgeon

Re: Evaluation of Adenoid Hypertrophy

Patient: 10-year-old male

Provisional Diagnosis: Adenoid hypertrophy with radiographic nasopharyngeal airway narrowing (ICD-10-CM: J35.2).

Investigations: Lateral nasopharyngeal X-ray dated 12 October 2026.

Radiological Findings:

  • Soft tissue swelling at the posterior nasopharyngeal wall.
  • Mild to moderate compression of the nasopharyngeal air column.
  • Impression: Mild to moderate adenoid hypertrophy.

Clinical History: Presenting symptoms and relevant clinical examination findings are not yet documented.

Reason for Referral:

Kindly evaluate the patient clinically for symptomatic adenoid hypertrophy and associated upper airway obstruction.

Please assess the nasal airway, palatine tonsils and middle-ear status. Flexible nasopharyngoscopy may be performed if clinically indicated.

Assessment for sleep-disordered breathing, otitis media with effusion and hearing impairment is requested as appropriate.

Kindly advise regarding conservative management versus surgical intervention based on clinical findings.

Thank you.


ā§§ā§§. OVERVIEW / FINAL CLINICAL SUMMARY

Clinical ParameterAssessment
Patient10-year-old male
InvestigationX-ray Nasopharynx, Lateral View
Report Date12 October 2026
Main AbnormalityEnlarged adenoid tissue
Airway FindingMild to moderate narrowing
Radiological DiagnosisMild to Moderate Adenoid Hypertrophy
ICD-10-CMJ35.2
Confirmed CauseNot established
Confirmed Sleep ApneaNot established
First SpecialistENT & Head-Neck Surgeon
Priority InvestigationENT examination Âą Flexible Nasopharyngoscopy
TreatmentSymptom-directed; conservative or surgical according to clinical indications

đŸŽ¯ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āφāĻŽāĻžāϰ āĻĒā§āϰāĻ¸ā§āϤāĻžāĻŦāĻŋāϤ Diagnosis

Provisional Dx: Adenoid Hypertrophy (J35.2)

Supporting investigation: X-ray evidence of mild-to-moderate adenoid hypertrophy with nasopharyngeal airway narrowing.

āĻāϟāĻŋāχ āĻŦāĻ°ā§āϤāĻŽāĻžāύ āϤāĻĨā§āϝ āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āϏāĻŦāĻšā§‡āϝāĻŧ⧇ āϝāĻĨāĻžāϝāĻĨ āĻāĻŦāĻ‚ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻ—āϤāĻ­āĻžāĻŦ⧇ āϏāĻŽāĻ°ā§āĻĨāύāϝ⧋āĻ—ā§āϝ diagnosisāĨ¤


⧧⧍. ACTIONABLE PLAN

āĻŦāĻ°ā§āϤāĻŽāĻžāύ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ: āĻĒā§āϰāĻĨāĻŽā§‡ ENT specialist-āĻāϰ clinical assessment āĻ•āϰāĻžāύ⧋ āωāϚāĻŋāϤāĨ¤ āĻļ⧁āϧ⧁ āĻāχ X-ray āĻĻ⧇āϖ⧇ āĻ…āĻĒāĻžāϰ⧇āĻļāύ āĻŦāĻž āĻĻā§€āĻ°ā§āϘāĻŽā§‡āϝāĻŧāĻžāĻĻāĻŋ āĻ“āώ⧁āϧ⧇āϰ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ āύ⧇āĻ“āϝāĻŧāĻž āĻ āĻŋāĻ• āĻšāĻŦ⧇ āύāĻžāĨ¤

āϝāĻĻāĻŋ āĻļāĻŋāĻļ⧁āϰ āύāĻŋāϝāĻŧāĻŽāĻŋāϤ āύāĻžāĻ• āĻĄāĻžāĻ•āĻž, āϘ⧁āĻŽā§‡ āĻļā§āĻŦāĻžāϏ āĻŦāĻ¨ā§āϧ āĻšāĻ“āϝāĻŧāĻž, āĻŽā§āĻ– āĻĻāĻŋāϝāĻŧ⧇ āĻļā§āĻŦāĻžāϏ āύ⧇āĻ“āϝāĻŧāĻž āĻ•āĻŋāĻ‚āĻŦāĻž āĻ•āĻžāύ⧇ āĻ•āĻŽ āĻļā§‹āύāĻžāϰ āχāϤāĻŋāĻšāĻžāϏ āĻĨāĻžāϕ⧇, āϤāĻžāĻšāϞ⧇ āϏ⧇āϗ⧁āϞ⧋ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻĒā§āϰāĻ­āĻžāĻŦ āĻĢ⧇āϞāĻŦ⧇āĨ¤

REFERENCES — TEXTBOOKS, GUIDELINES & JOURNALS

Textbook references

  1. Cummings Otolaryngology: Head and Neck Surgery. 7th ed. Elsevier; 2021. Pediatric upper airway and adenotonsillar disease sectionsāĨ¤
  2. Nelson Textbook of Pediatrics. 22nd ed. Elsevier; 2024. Pediatric upper airway obstruction and sleep-disordered breathing sectionsāĨ¤

Clinical guidelines and peer-reviewed evidence

  1. Ahmad Z, et al. Adenoid hypertrophy—diagnosis and treatment: the new S2k guideline. HNO. 2023;71(Suppl 1):67–72. DOI: 10.1007/s00106-023-01299-6.
  2. American Academy of Otolaryngology–Head and Neck Surgery. Clinical Indicators: Adenoidectomy. 2014. āĻŦāĻ°ā§āϤāĻŽāĻžāύ⧇ āϏāĻ‚āĻ¸ā§āĻĨāĻžāϰ āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻžāϧ⧀āύ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāĻ• āĻĻāϞāĻŋāϞāĨ¤
  3. Marcus CL, et al. Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome. Pediatrics. 2012;130(3):576–584. DOI: 10.1542/peds.2012-1671.
  4. Nixon GM, et al. Intranasal Treatments for Children With Sleep-Disordered Breathing: The MIST+ Randomized Clinical Trial. JAMA Pediatrics. 2026;180(3):240–249. DOI: 10.1001/jamapediatrics.2025.5717.
  5. Sousa-Pinto B, et al. ARIA-EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments. Allergy. DOI: 10.1111/all.70131.

Prescription attached:-

đŸŠē LIPU MED — FULL BILINGUAL CLINICAL CASE REVIEW

TC(1472).(12) ¡ ENT Department Case No (109) ¡ Website-sequence-checked draft

Adenoid Hypertrophy with Physician-Documented Adenotonsillitis & Possible Otitis Media

āĻ…ā§āϝāĻžāĻĄāĻŋāĻ¨ā§Ÿā§‡āĻĄ āĻŦ⧜ āĻšāĻ“ā§ŸāĻž, āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϞ⧇āĻ–āĻž āĻ…ā§āϝāĻžāĻĄāĻŋāύ⧋-āϟāύāϏāĻŋāϞāĻžāχāϟāĻŋāϏ āĻ“ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻŽāĻ§ā§āϝāĻ•āĻ°ā§āϪ⧇āϰ āϰ⧋āĻ—

1 Prescription ¡ 2 Radiology Inputs ¡ 17 Sections ¡ MedEx Sources

01. Case identification, TC, department | āϕ⧇āϏ āĻĒāϰāĻŋāϚāĻŋāϤāĻŋ, āϟāĻŋāϏāĻŋ āĻ“ āĻŦāĻŋāĻ­āĻžāĻ—

Proposed publication title â€” TC(1472).(12). ENT Department Case No (109): Radiographically Confirmed Adenoid Hypertrophy with Physician-Documented Adenotonsillitis and Possible Concurrent Otitis Media — Pediatric Prescription Safety Review (1 Prescription + 2 Reports). Confidence: 0.99 (website sequence at verification time)

TC = Total Case â€” āϏāĻ°ā§āĻŦāĻŽā§‹āϟ āϕ⧇āϏ⧇āϰ āĻĒā§āϰāĻ¸ā§āϤāĻžāĻŦāĻŋāϤ āϏāĻŋāϰāĻŋ⧟āĻžāϞ; DCS = 12 â€” ENT āĻŦāĻŋāĻ­āĻžāϗ⧇āϰ āĻ•ā§āϝāĻžāĻŸā§‡āĻ—āϰāĻŋ āϏāĻŋāϰāĻŋ⧟āĻžāϞ; Department Case No = 109 â€” āύāϤ⧁āύ ENT āϕ⧇āϏ⧇āϰ āĻĒā§āϰāĻ¸ā§āϤāĻžāĻŦāĻŋāϤ āύāĻŽā§āĻŦāϰāĨ¤ āĻ“ā§Ÿā§‡āĻŦāϏāĻžāχāĻŸā§‡ āĻĻ⧇āĻ–āĻž āϏāĻ°ā§āĻŦāĻļ⧇āώ āĻĒā§āϰāĻ•āĻžāĻļāĻŋāϤ āĻĒā§‹āĻ¸ā§āϟ TC(1471), ENT Department Case 108; āϤāĻžāχ TC(1472)/ENT109 āĻļ⧁āϧ⧁ āύāϤ⧁āύ āĻ–āϏ⧜āĻžāϰ āĻĒā§āϰāĻ¸ā§āϤāĻžāĻŦ, āĻĒā§āϰāĻ•āĻžāĻļ⧇āϰ āφāϗ⧇ āύāĻŽā§āĻŦāϰ āφāĻŦāĻžāϰ āĻŽāĻŋāϞāĻŋā§Ÿā§‡ āύāĻŋāϤ⧇ āĻšāĻŦ⧇āĨ¤

Original source field | āĻŽā§‚āϞ āύāĻĨāĻŋDocumented value | āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ āϤāĻĨā§āϝ
Patient name | āύāĻžāĻŽRadiology: Md. Mahamud; prescription print: MAH,MUD (āĻŦāĻžāύāĻžāύ⧇ āĻ‰ā§ŽāϏāϭ⧇āĻĻ⧇ āĻĒāĻžāĻ°ā§āĻĨāĻ•ā§āϝ)āĨ¤
Age / sex | āĻŦ⧟āϏ/āϞāĻŋāĻ™ā§āĻ—10 years / Male — ā§§ā§Ļ āĻŦāĻ›āϰ / āϛ⧇āϞ⧇āĨ¤
Institution | āĻšāĻžāϏāĻĒāĻžāϤāĻžāϞNational Institute of ENT, Tejgaon, Dhaka, Bangladesh — āϜāĻžāĻ¤ā§€ā§Ÿ āύāĻžāĻ•-āĻ•āĻžāύ-āĻ—āϞāĻž āχāύāĻ¸ā§āϟāĻŋāϟāĻŋāωāϟāĨ¤
Prescription date | āĻŦā§āϝāĻŦāĻ¸ā§āĻĨāĻžāĻĒāĻ¤ā§āϰ18 October 2026 — ā§§ā§Ž āĻ…āĻ•ā§āĻŸā§‹āĻŦāϰ ⧍ā§Ļ⧍ā§ŦāĨ¤
Radiology facility | āĻĒāϰ⧀āĻ•ā§āώāĻžPopular Diagnostic Centre, Jatrabari Branch; X-ray dated 12 October 2026.
Registration / room | āϰ⧇āϜāĻŋ/āĻ•āĻ•ā§āώNIENT: 0095709; Room no. 05; token/serial appears 72.
Original prescriber | āĻŽā§‚āϞ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ•Handwritten signature present but name and degree not legible â€” āύāĻžāĻŽ/āĻĄāĻŋāĻ—ā§āϰāĻŋ āύāĻŋāĻļā§āϚāĻŋāϤ āĻĒāĻžāĻ āϝ⧋āĻ—ā§āϝ āύ⧟āĨ¤
X-ray referral | āĻāĻ•ā§āϏ-āϰ⧇ āϰ⧇āĻĢāĻžāϰAsso. Prof. Dr. Tariqul Islam (Tareq), MBBS, BCS (Health), FCPS (ENT), MS (ENT), as stated on radiology report; not established as author of this later prescription.

Publication privacy note | āĻĒā§āϰāĻ•āĻžāĻļāύāĻžāϰ āĻ—ā§‹āĻĒāĻ¨ā§€ā§ŸāϤāĻž: ā§§ā§Ļ āĻŦāĻ›āϰ⧇āϰ āĻļāĻŋāĻļ⧁āϰ āύāĻžāĻŽ āĻ“ āĻšāĻžāϏāĻĒāĻžāϤāĻžāϞ⧇āϰ āĻĒāϰāĻŋāϚ⧟ āĻĒā§āϰāĻ•āĻžāĻļ⧇āϰ āϜāĻ¨ā§āϝ āĻ…āĻ­āĻŋāĻ­āĻžāĻŦāϕ⧇āϰ āωāĻĒāϝ⧁āĻ•ā§āϤ āϏāĻŽā§āĻŽāϤāĻŋ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰ⧁āύāĨ¤

02. C/C and clinical history | āĻĒā§āϰāϧāĻžāύ āĻ…āĻ­āĻŋāϝ⧋āĻ— āĻ“ āϰ⧋āĻ—ā§€āϰ āχāϤāĻŋāĻšāĻžāϏ

Documented C/C (Chief Complaint) | āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϞ⧇āĻ–āĻž āĻĒā§āϰāϧāĻžāύ āĻ…āĻ­āĻŋāϝ⧋āĻ—: āϕ⧋āύ⧋ āĻĒ⧃āĻĨāĻ• chief-complaint section āĻŦāĻž āωāĻĒāϏāĻ°ā§āϗ⧇āϰ āĻŦāĻ°ā§āĻŖāύāĻž āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāύāĻŋāĨ¤ Confidence 0.98

ParameterSource finding | āĻ‰ā§ŽāϏ⧇ āϝāĻž āφāϛ⧇Clinical assessment | āĻŦā§āϝāĻžāĻ–ā§āϝāĻž
C/C | āĻĒā§āϰāϧāĻžāύ āĻ…āĻ­āĻŋāϝ⧋āĻ—Not written | āϞ⧇āĻ–āĻž āύ⧇āχNasal blockage, snoring, sore throat, ear pain/hearing loss must be elicited, not asserted â€” āĻāϏāĻŦ āϜāĻŋāĻœā§āĻžāĻžāϏāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇, āϰ⧋āĻ—ā§€ āĻŦāϞ⧇āϛ⧇āύ āĻŦāϞ⧇ āϞ⧇āĻ–āĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤
I/H | Illness historyNot written | āϞ⧇āĻ–āĻž āύ⧇āχDuration of fever, cold, nasal obstruction, throat/ear symptoms unknown — āĻ…āϜāĻžāύāĻžāĨ¤
O/H | Operative historyNot writtenāϏāĻžāĻ°ā§āϜāĻžāϰāĻŋāϰ āχāϤāĻŋāĻšāĻžāϏ āĻ…āϜāĻžāύāĻžāĨ¤
D/H | Drug historyNot writtenāφāϗ⧇ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāĻ•/āĻ¸ā§āĻŸā§‡āĻ°ā§Ÿā§‡āĻĄ āύ⧇āĻ“ā§ŸāĻž āĻ“ drug allergy āĻ…āϜāĻžāύāĻžāĨ¤
M/H | Medical historyNot writtenāĻ…ā§āϝāĻžāϜāĻŽāĻž, āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ, āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ āϰ⧋āĻ— āĻ…āϜāĻžāύāĻžāĨ¤
O/S/E | Otoscopic examinationPossible ear diagnoses noted, objective findings absentāĻ•āĻžāύ⧇āϰ āĻĒāĻ°ā§āĻĻāĻžāϰ āϰāĻ™/āĻĢā§‹āϞāĻž/āϤāϰāϞ/āύ⧜āĻžāϚ⧜āĻž āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤
O/G/E | General examinationNot writtenVital signs, weight, SpO₂, throat/tonsil grade not recorded.
Family / exposure / immunisationNot writtenāĻĒāĻžāϰāĻŋāĻŦāĻžāϰāĻŋāĻ•, āϧ⧂āĻŽāĻĒāĻžāύ āĻāĻ•ā§āϏāĻĒā§‹āϜāĻžāϰ āĻ“ āϟāĻŋāĻ•āĻžāĻĻāĻžāύ āχāϤāĻŋāĻšāĻžāϏ āĻ…āϜāĻžāύāĻžāĨ¤

Working symptom hypotheses | āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āωāĻĒāϏāĻ°ā§āĻ—: āύāĻžāĻ• āĻŦāĻ¨ā§āϧ, āύāĻžāĻ• āĻĄāĻžāĻ•āĻž, āĻŽā§āĻ– āĻĻāĻŋā§Ÿā§‡ āĻļā§āĻŦāĻžāϏ, āĻ—āϞāĻž āĻŦā§āϝāĻĨāĻž āĻŦāĻž āĻ•āĻžāύ⧇ āϏāĻŽāĻ¸ā§āϝāĻž āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāĻ°ā§‡â€”āĻāϗ⧁āϞ⧋ āĻ“āώ⧁āϧ āĻ“ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āĻĻ⧇āϖ⧇ āĻ…āύ⧁āĻŽāĻžāύ; āύāĻŋāĻļā§āϚāĻŋāϤ C/C āύ⧟āĨ¤ Confidence 0.50

03. Original physician’s diagnosis | āĻŽā§‚āϞ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

  • “Adeno-Tonsillitis” â€” āĻ…ā§āϝāĻžāĻĄāĻŋāĻ¨ā§Ÿā§‡āĻĄ āĻ“ āĻĒā§āϝāĻžāϞāĻžāϟāĻžāχāύ āϟāύāϏāĻŋāϞ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻš; āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻšāĻžāϤ⧇ āϞ⧇āĻ–āĻž āĻšāĻŋāϏ⧇āĻŦ⧇ āϤ⧁āϞāύāĻžāĻŽā§‚āϞāĻ• āĻ¸ā§āĻĒāĻˇā§āϟāĨ¤ Confidence 0.90
  • “AOM (R?)” â€” āϏāĻŽā§āĻ­āĻŦāϤ āĻĄāĻžāύ āĻ•āĻžāύ⧇āϰ Acute Otitis Media (āϤ⧀āĻŦā§āϰ āĻŽāĻ§ā§āϝāĻ•āĻ°ā§āϪ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻš)āĨ¤ āĻļāĻŦā§āĻĻ/āĻĒāĻžāĻļ āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟āĨ¤ Confidence 0.58
  • “OME (Lt?)” â€” āϏāĻŽā§āĻ­āĻŦāϤ āĻŦāĻžāĻŽ āĻ•āĻžāύ⧇āϰ Otitis Media with Effusion (āĻŽāĻ§ā§āϝāĻ•āĻ°ā§āϪ⧇ āĻĒā§āϰāĻĻāĻžāĻšāĻšā§€āύ/āĻ…-āϤ⧀āĻŦā§āϰ āϤāϰāϞ āϜāĻŽāĻž)āĨ¤ āĻĒāĻžāĻļ āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟āĨ¤ Confidence 0.72

Safety distinction: AOM = acute bacterial/viral inflammatory ear syndrome; OME = middle-ear effusion without acute infection findings. āĻāĻ•āχ āĻ…āĻŦāĻ¸ā§āĻĨāĻž āύ⧟āĨ¤ āĻāĻ•ā§āϏ-āϰ⧇ āύāĻžāϏ⧋āĻĢā§āϝāĻžāϰāĻŋāĻ‚āĻ•ā§āϏ⧇āϰ; āĻāϟāĻŋ āĻ•āĻžāύ āĻŦāĻž āϟāύāϏāĻŋāϞ⧇āϰ āϰ⧋āĻ— āĻ¸ā§āĻŦāĻžāϧ⧀āύāĻ­āĻžāĻŦ⧇ āĻĒā§āϰāĻŽāĻžāĻŖ āĻ•āϰ⧇ āύāĻžāĨ¤

04. O/E and clinical findings | āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ“ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻĒāĻ°ā§āϝāĻŦ⧇āĻ•ā§āώāĻŖ

Written observations: āύāĻžāϏāĻžāϞ/āĻĢā§āϝāĻžāϰāĻŋāĻžā§āϜāĻŋ⧟āĻžāϞ āĻāĻ¨ā§āĻĄā§‹āĻ¸ā§āĻ•āĻĒāĻŋ, āϟāύāϏāĻŋāϞ⧇āϰ grade, temperature, eardrum findings, auscultation, vitals āĻŦāĻž weight āϕ⧋āύāĻ“āϟāĻŋ āĻ¸ā§āĻĒāĻˇā§āϟāĻ­āĻžāĻŦ⧇ āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ āύ⧇āχāĨ¤ Confidence 0.97

Clinician should record: bilateral pneumatic otoscopy (āĻĻ⧁āχ āĻ•āĻžāύ⧇āϰ āĻĒāĻ°ā§āĻĻāĻžāϰ āϚāϞāύ āĻĒāϰ⧀āĻ•ā§āώāĻž), ear canal, tonsillar size/exudate, nasal discharge, turbinates, adenoid symptoms, neck nodes, sleep-related breathing, hearing and speech, vital signs, weight and hydration. Confidence 0.95 (guideline standard)

05. Investigations: report 1 and report 2 | āϰāĻŋāĻĒā§‹āĻ°ā§āϟ āĻ“ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞ

Source | āύāĻĨāĻŋOriginal English | āχāĻ‚āϰ⧇āϜāĻŋBangla clinical meaning | āĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻž
Report 1: Written X-ray, 12-10-2026“Soft tissue swelling is seen in posterior wall nasopharynx.”āύāĻžāϏ⧋āĻĢā§āϝāĻžāϰāĻŋāĻ‚āĻ•ā§āϏ⧇āϰ āĻĒ⧇āĻ›āύ⧇āϰ āĻĻā§‡ā§ŸāĻžāϞ⧇ āύāϰāĻŽ āϟāĻŋāĻ¸ā§āϝ⧁āϰ āĻŦ⧃āĻĻā§āϧāĻŋ/āĻĢā§‹āϞāĻžāĻ­āĻžāĻŦāĨ¤
Report 1“Nasopharyngeal air column is mild to moderately compressed.”āύāĻžāϕ⧇āϰ āĻĒ⧇āĻ›āύ⧇āϰ āĻŦāĻžā§Ÿā§āĻĒāĻĨ āĻŽā§ƒāĻĻ⧁ āĻĨ⧇āϕ⧇ āĻŽāĻžāĻāĻžāϰāĻŋ āϏāϰ⧁āĨ¤
Report 1“Cervical spine appears normal.”āĻĻ⧃āĻļā§āϝāĻŽāĻžāύ āĻ—āϞāĻžāϰ āĻŽā§‡āϰ⧁āĻĻāĻŖā§āĻĄ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ•āĨ¤
Report 1“Mild to moderate adenoid hypertrophy.”āĻ…ā§āϝāĻžāĻĄāĻŋāĻ¨ā§Ÿā§‡āĻĄ āĻŽā§ƒāĻĻ⧁ āĻĨ⧇āϕ⧇ āĻŽāĻžāĻāĻžāϰāĻŋ āĻŦ⧜ āĻšāĻ“ā§ŸāĻžāϰ āϰ⧇āĻĄāĻŋāĻ“āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤāĨ¤
Report 2: Film photographLateral nasopharyngeal X-ray film; glare and angle limit independent grading.āĻāĻ•ā§āϏ-āϰ⧇ āĻĢāĻŋāĻ˛ā§āĻŽā§‡āϰ āĻŽā§‹āĻŦāĻžāχāϞ āĻ›āĻŦāĻŋāϤ⧇ āĻĒā§āϰāϤāĻŋāĻĢāϞāύ; āύāĻŋāĻ°ā§āϭ⧁āϞ āĻ—ā§āϰ⧇āĻĄ/āĻŦāĻžāϧāĻžāϰ āĻļāϤāĻ•āϰāĻž āĻšāĻŋāϏāĻžāĻŦ āĻ•āϰāĻž āϝāĻžā§Ÿ āύāĻžāĨ¤
Prescription investigation/advicePossibly “PTA + SRT + medical” (handwriting uncertain).PTA = Pure Tone Audiometry (āĻļā§āϰāĻŦāĻŖāĻŽāĻžāĻ¤ā§āϰāĻž āĻĒāϰ⧀āĻ•ā§āώāĻž); SRT = Speech Reception Threshold (āĻ•āĻĨāĻž āĻļ⧁āύ⧇ āĻŦā§‹āĻāĻžāϰ āϏ⧀āĻŽāĻž); āĻĒāϰ⧀āĻ•ā§āώāĻž āĻĻ⧇āĻ“ā§ŸāĻž/āĻļ⧇āώ āĻšā§Ÿā§‡āĻ›ā§‡â€”āϤāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟āĨ¤

Important: Only adenoid hypertrophy is corroborated by radiology. Tonsillitis, AOM and OME require separate clinical examination. Confidence 0.97

06. Definition | āϰ⧋āϗ⧇āϰ āϏāĻ‚āĻœā§āĻžāĻž

Adenoid hypertrophy â€” āύāĻžāϕ⧇āϰ āĻĒ⧇āĻ›āύ⧇āϰ lymphoid tissue āĻŦāĻž pharyngeal tonsil āφāĻ•āĻžāϰ⧇ āĻŦ⧜ āĻšāĻ“ā§ŸāĻž; āĻ•āĻŋāϛ⧁ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āύāĻžāϕ⧇āϰ āĻĒ⧇āĻ›āύ⧇āϰ āĻŦāĻžā§Ÿā§āĻĒāĻĨ āĻŦāĻžāϧāĻžāĻ—ā§āϰāĻ¸ā§āϤ āĻšā§ŸāĨ¤ Confidence: 0.98

Adenotonsillitis â€” āĻ…ā§āϝāĻžāĻĄāĻŋāĻ¨ā§Ÿā§‡āĻĄ āĻ“ āĻĒā§āϝāĻžāϞāĻžāϟāĻžāχāύ āϟāύāϏāĻŋāϞ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻš/āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻž; āĻŦāĻ°ā§āϧāĻŋāϤ āφāĻ•āĻžāϰ āĻĨāĻžāĻ•āĻž āĻŽāĻžāύ⧇āχ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āύ⧟āĨ¤ Confidence: 0.98

Acute otitis media (AOM) â€” āĻŽāĻ§ā§āϝāĻ•āĻ°ā§āϪ⧇āϰ āϤ⧀āĻŦā§āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻŦāĻž āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ; āĻ•āĻžāύ⧇āϰ āĻĒāĻ°ā§āĻĻāĻžā§Ÿ characteristic bulging/effusion āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤ Confidence: 0.98

Otitis media with effusion (OME) â€” āϤ⧀āĻŦā§āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϞāĻ•ā§āώāĻŖ āĻ›āĻžā§œāĻž āĻŽāĻ§ā§āϝāĻ•āĻ°ā§āϪ⧇ āϤāϰāϞ āϜāĻŽāĻžāĨ¤ Confidence: 0.98

07. Etiology and pathophysiology | āĻ•āĻžāϰāĻŖ āĻ“ āϰ⧋āĻ—āϏ⧃āĻˇā§āϟāĻŋāϰ āĻĒā§āϰāĻ•ā§āϰāĻŋ⧟āĻž

  • Age-related lymphoid growth | āĻŦ⧟āϏ-āϏāĻŽā§āĻĒāĻ°ā§āĻ•āĻŋāϤ āϞāĻŋāĻŽā§āĻĢā§Ÿā§‡āĻĄ āĻŦ⧃āĻĻā§āϧāĻŋ: āĻļāĻŋāĻļ⧁ āĻŦ⧟āϏ⧇ adenoid āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ•āĻ­āĻžāĻŦ⧇āĻ“ āϤ⧁āϞāύāĻžāĻŽā§‚āϞāĻ• āĻŦ⧜ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ 0.95
  • Repeated viral/bacterial exposure | āĻŦāĻžāϰāĻŦāĻžāϰ āĻœā§€āĻŦāĻžāϪ⧁āϰ āϏāĻ‚āĻ¸ā§āĻĒāĻ°ā§āĻļ: āĻĒā§āϰāĻĻāĻžāĻšā§‡āϰ āĻ•āĻžāϰāϪ⧇ lymphoid tissue āĻŦ⧜/āĻ¸ā§āĻĢā§€āϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇; āĻāχ āϰ⧋āĻ—ā§€āϰ āĻ•āĻžāϰāĻŖ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āύ⧟āĨ¤ 0.88
  • Rhinitis or allergy | āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ: āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ nasal symptoms āĻŦāĻžā§œāĻžāϤ⧇ āĻĒāĻžāϰ⧇; āĻļ⧁āϧ⧁ āĻāχ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āĻĨ⧇āϕ⧇ allergy āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟āĨ¤ 0.84
  • Eustachian tube dysfunction | āĻ•āĻžāύ⧇āϰ āĻŦāĻžāϤāĻžāϏ āϚāϞāĻžāϚāϞ⧇āϰ āύāĻžāϞāĻŋāϰ āĻ…āĻ•āĻžāĻ°ā§āϝāĻ•āĻžāϰāĻŋāϤāĻž: āĻ…ā§āϝāĻžāĻĄāĻŋāĻ¨ā§Ÿā§‡āĻĄ/āύāĻžāϏ⧋āĻĢā§āϝāĻžāϰāĻŋāĻžā§āϜāĻŋ⧟āĻžāϞ āĻĒā§āϰāĻĻāĻžāĻšā§‡āϰ āϏāĻ™ā§āϗ⧇ OME āϝ⧁āĻ•ā§āϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ 0.92

08. Clinical features and missing data | āωāĻĒāϏāĻ°ā§āĻ— āĻ“ āĻ…āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ āϤāĻĨā§āϝ

Possible clinical feature | āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϞāĻ•ā§āώāĻŖMust be confirmed | āϝāĻžāϚāĻžāχ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ
Nasal obstruction — āύāĻžāĻ• āĻŦāĻ¨ā§āϧāĻĻāĻŋāύ/āϰāĻžāϤ, āĻāĻ•/āωāϭ⧟ āĻĻāĻŋāĻ•, āĻ•āϤāĻĻāĻŋāύ?
Mouth breathing / snoring — āĻŽā§āĻ– āĻĻāĻŋā§Ÿā§‡ āĻļā§āĻŦāĻžāϏ/āύāĻžāĻ• āĻĄāĻžāĻ•āĻžāϘ⧁āĻŽā§‡ breathing pauses, gasping, restless sleep?
Tonsillitis symptoms — āϟāύāϏāĻŋāϞ āĻĒā§āϰāĻĻāĻžāĻšāĻœā§āĻŦāϰ, āĻ—āϞāĻž āĻŦā§āϝāĻĨāĻž, āĻ—āĻŋāϞāϤ⧇ āĻ•āĻˇā§āϟ, exudate?
AOM — āϤ⧀āĻŦā§āϰ āĻŽāĻ§ā§āϝāĻ•āĻ°ā§āĻŖ āĻĒā§āϰāĻĻāĻžāĻšāĻ•āĻžāύ⧇ āĻŦā§āϝāĻĨāĻž, āĻœā§āĻŦāϰ, āĻ•āĻžāύ⧇āϰ āĻĒāĻ°ā§āĻĻāĻž āĻĢā§‹āϞāĻž/āϞāĻžāϞ?
OME — āĻ•āĻžāύ⧇ āϤāϰāϞāĻļā§āϰāĻŦāĻŖ āĻ•āĻŽā§‡ āϝāĻžāĻ“ā§ŸāĻž, āĻ­āϰāĻžāϟ āĻ…āύ⧁āĻ­ā§‚āϤāĻŋ, tympanogram?
Other alarm signs — āϏāϤāĻ°ā§āĻ•āϤāĻžāĻļā§āĻŦāĻžāϏāĻ•āĻˇā§āϟ, āĻ–āĻžāĻŦāĻžāϰ/āĻĒāĻžāύāĻŋ āĻ—āĻŋāϞāϤ⧇ āύāĻž āĻĒāĻžāϰāĻž, mastoid tenderness, severe headache?

āĻāϗ⧁āϞ⧋ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ…āύ⧁āϏāĻ¨ā§āϧāĻžāύ⧇āϰ āϤāĻžāϞāĻŋāĻ•āĻž; āϏ⧁āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϰ⧋āĻ—ā§€āϰ āϞāĻŋāĻ–āĻŋāϤ symptom āύ⧟āĨ¤ Source completeness 0.98

09. Differential diagnosis | āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

  • Allergic rhinitis — āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āύāĻžāϕ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻš; sneezing, nasal itch, watery discharge.
  • Recurrent viral upper respiratory infection — āĻŦāĻžāϰāĻŦāĻžāϰ āĻ­āĻžāχāϰāĻžāϞ āĻļā§āĻŦāĻžāϏāϤāĻ¨ā§āĻ¤ā§āϰ⧇āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤
  • Bacterial tonsillopharyngitis — āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϜāύāĻŋāϤ āϟāύāϏāĻŋāϞ/āĻ—āϞāĻžāĻŦā§āϝāĻĨāĻž; āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϞ⧇ GAS testāĨ¤
  • Chronic adenoiditis — āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ āĻ…ā§āϝāĻžāĻĄāĻŋāĻ¨ā§Ÿā§‡āĻĄ āĻĒā§āϰāĻĻāĻžāĻšāĨ¤
  • Turbinate hypertrophy / sinus disease — āύāĻžāϕ⧇āϰ āϭ⧇āϤāϰ⧇āϰ āϟāĻŋāĻ¸ā§āϝ⧁ āĻŦ⧜ āĻŦāĻž āϏāĻžāχāύāĻžāϏ⧇āϰ āϰ⧋āĻ—āĨ¤
  • Tonsillar hypertrophy with sleep-disordered breathing — āϟāύāϏāĻŋāϞ āĻŦ⧜ āĻšāĻ“ā§ŸāĻžā§Ÿ āϘ⧁āĻŽā§‡ āĻļā§āĻŦāĻžāϏ⧇ āĻŦāĻžāϧāĻžāĨ¤

Final differentiation: Nasopharyngeal X-ray alone cannot classify the cause of sore throat or ear disease. 0.96

10. Prescribed drugs: transcription and verification | āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āĻ“āώ⧁āϧ⧇āϰ āϤāĻžāϞāĻŋāĻ•āĻž āĻ“ āϝāĻžāϚāĻžāχ

#Handwritten interpretation | āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ“āώ⧁āϧGeneric | āĻŽā§‚āϞ āωāĻĒāĻžāĻĻāĻžāύIdentification | āύāĻŋāĻļā§āϚāĻŋāϤāϤāĻžāϰ āĻŽāĻžāĻ¤ā§āϰāĻž
1Clacido 375 (looks Clacido/Clavido)Amoxicillin 250 mg + Clavulanic acid 125 mgHigh — 0.86
2Xalcort 18Deflazacort 18 mgHigh — 0.94
3Paricel 10 (name difficult)Rabeprazole sodium 10 mg if correctly readModerate — 0.72
4Afrin N/D (strength unclear)Oxymetazoline; 0.05% vs 0.025% not establishedHigh for name — 0.89
5Momes- nasal spray (Momeson / Momespray cannot be distinguished)Likely mometasone furoate 50 mcg/sprayModerate — 0.72
6Trilock 5Montelukast 5 mgHigh — 0.91

Prescription dose caveat: āϰ⧇āϜāĻŋāĻŽā§‡āύ⧇āϰ āĻ•āĻŋāϛ⧁ āϏāĻ‚āĻ–ā§āϝāĻž āĻšāĻžāϤ⧇ āϞ⧇āĻ–āĻž āĻ…āĻ¸ā§āĻĒāĻˇā§āϟāĨ¤ Clacido āϏāĻŽā§āĻ­āĻŦāϤ ā§§+ā§§+ā§§, Xalcort āϏāĻŽā§āĻ­āĻŦāϤ ā§§+ā§Ļ+ā§Ļ, Paricel ā§§+ā§Ļ+ā§§ āĻāĻŦāĻ‚ Trilock ā§Ļ+ā§Ļ+ā§§; āĻ•āĻŋāĻ¨ā§āϤ⧁ weight āĻ“ pharmacy label āĻ›āĻžā§œāĻž āĻāϗ⧁āϞ⧋ āĻ…āύ⧁āϏāϰāĻŖāϝ⧋āĻ—ā§āϝ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āύ⧟āĨ¤ āĻŦāĻŋāĻļ⧇āώ āĻ•āϰ⧇ intranasal mometasone-āĻāϰ āϚāĻžāĻĒ āĻ“ āĻĻ⧈āύāĻŋāĻ• āĻŦāĻžāϰ āĻ…āĻŦāĻļā§āϝāχ āϝāĻžāϚāĻžāχ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

11. MedEx individual medicine reviews — 17 parameters each | āĻĒā§āϰāϤāĻŋāϟāĻŋ āĻ“āώ⧁āϧ⧇āϰ ā§§ā§­āϟāĻŋ āϤāĻĨā§āϝ

1. Clacido 375 mg — āĻ•ā§āϞāĻžāϏāĻŋāĻĄā§‹ Identification confidence: 0.86

1. Generic name | āĻœā§‡āύ⧇āϰāĻŋāĻ•

Amoxicillin 250 mg + Clavulanic acid 125 mg — āĻ…ā§āϝāĻžāĻŽāĻ•ā§āϏāĻŋāϏāĻŋāϞāĻŋāύ āĻ“ āĻ•ā§āϞāĻžāϭ⧁āϞāĻžāύ⧇āϟāĨ¤

2. Brand name | āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Clacido 375 mg (Healthcare Pharmaceuticals Ltd.) — āĻšāĻžāϤ⧇ āϞ⧇āĻ–āĻž āύāĻžāĻŽā§‡āϰ āϏāĻŦāĻšā§‡ā§Ÿā§‡ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻŽāĻŋāϞāĨ¤

3. MedEx alternate brand | āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Moxaclav 250/125, Augment 250/125, Clamox 250/125 — āĻāĻ•āχ āωāĻĒāĻžāĻĻāĻžāύ⧇āϰ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄāĨ¤

4. MedEx therapeutic class | āĻĨ⧇āϰāĻžāĻĒāĻŋāωāϟāĻŋāĻ• āĻ•ā§āϞāĻžāϏ

Broad spectrum penicillins — āĻŦāĻŋāĻ¸ā§āϤ⧃āϤ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āώāĻŽāϤāĻžāϰ āĻĒ⧇āύāĻŋāϏāĻŋāϞāĻŋāύāĨ¤

5. Pharmacological class | āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Beta-lactam antibiotic + beta-lactamase inhibitor — āĻŦāĻŋāϟāĻž-āĻ˛ā§āϝāĻžāĻ•āϟāĻžāĻŽ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāĻ• āĻ“ āĻāύāϜāĻžāχāĻŽ āĻĒā§āϰāϤāĻŋāϰ⧋āϧāĻ•āĨ¤

6. Use / purpose | āωāĻĻā§āĻĻ⧇āĻļā§āϝ

Bacterial ENT infections, selected otitis media/tonsillitis — āĻĒā§āϰāĻŽāĻžāĻŖāĻŋāϤ āĻŦāĻž āϏāĻ¨ā§āĻĻ⧇āĻšāϝ⧁āĻ•ā§āϤ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

7. Why possibly prescribed here | āĻāχ āϰ⧋āĻ—ā§€āϤ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ•āĻžāϰāĻŖ

āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ AOM/āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ tonsillitis āϭ⧇āĻŦ⧇ āĻĻ⧇āĻ“ā§ŸāĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇; āϤāĻŦ⧇ otoscopy āĻŦāĻž throat-test āĻĢāϞ āύ⧇āχāĨ¤

8. Adverse effects | āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

Diarrhoea, nausea, rash; rarely anaphylaxis, antibiotic-associated colitis, liver injury — āĻĒāĻžāϤāϞāĻž āĻĒāĻžā§ŸāĻ–āĻžāύāĻž, āĻŦāĻŽāĻŋ, āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ, āĻŦāĻŋāϰāϞ āϗ⧁āϰ⧁āϤāϰ āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻžāĨ¤

9. Direct MedEx link | āϏāϰāĻžāϏāϰāĻŋ āĻŽā§‡āĻĄā§‡āĻ•ā§āϏ āϞāĻŋāĻ‚āĻ•

Clacido — MedEx brand
Amoxicillin + Clavulanic acid — MedEx generic

10. Unit / strip price & other forms | āĻĻāĻžāĻŽ āĻ“ āĻ…āĻ¨ā§āϝ āĻĢāĻ°ā§āĻŽ

MedEx currently displays ā§ŗ30/tablet, ā§ŗ180/6-tablet strip, ā§ŗ540/18-tablet pack; some indexed snapshots show ā§ŗ25/tablet: live price may vary. āĻ…āĻ¨ā§āϝ āĻļāĻ•ā§āϤāĻŋ 625 mg, 1 g; oral suspension āĻ“ injectionāĨ¤

11. Mechanism of action | āĻ•āĻžāĻ°ā§āϝāĻĒāĻĻā§āϧāϤāĻŋ

Amoxicillin inhibits bacterial cell-wall cross-linking; clavulanate blocks some beta-lactamases — āϕ⧋āώāĻĒā§āϰāĻžāĻšā§€āϰ āϤ⧈āϰāĻŋāϤ⧇ āĻŦāĻžāϧāĻž āĻ“ āĻĒā§āϰāϤāĻŋāϰ⧋āϧ⧀ āĻāύāϜāĻžāχāĻŽ āĻĻāĻŽāύāĨ¤

12. Indications | āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ

Selected susceptible bacterial ENT, respiratory, urinary, skin, soft tissue infections — āϏāĻ‚āĻŦ⧇āĻĻāύāĻļā§€āϞ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϰ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāĨ¤

13. Interactions and contraindications | āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧ

Penicillin allergy and previous co-amoxiclav cholestatic jaundice contraindications; interactions with warfarin, allopurinol, methotrexate — āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻ“ āϞāĻŋāĻ­āĻžāϰ āϏāĻŽāĻ¸ā§āϝāĻžā§Ÿ āϏāϤāĻ°ā§āĻ•āϤāĻžāĨ¤

14. Precautions and warnings | āϏāϤāĻ°ā§āĻ•āϤāĻž

Weight, renal function, allergy and prior antibiotic history essential; antibiotic stewardship — āĻ“āϜāύ, āĻ•āĻŋāĻĄāύāĻŋ āĻ“ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āϜāĻžāύāϤ⧇ āĻšāĻŦ⧇āĨ¤

15. Dose and administration | āĻĄā§‹āϜ āĻ“ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

Possible Rx transcription: 1+1+1 for ~7 days (NOT confirmed). Ten-year-old dosage must be weight-based, not adult tablet schedules; verify amoxicillin/clavulanate ratio, indication and dosing with prescriber before giving.

16. Pregnancy and lactation | āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻĻ⧁āĻ—ā§āϧāĻĻāĻžāύ

Patient male child: not applicable; generally use in pregnancy/lactation only under clinician assessment.

17. Other compositions / combinations on MedEx | āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•āĻŽā§āĻĒā§‹āϜāĻŋāĻļāύ

250/125, 500/125, 875/125 tablets; (125/31.25)/5 mL and (400/57.5)/5 mL suspension; 600 mg and 1.2 g injections.

Critical prescription review | āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž: āϰāĻŋāĻĒā§‹āĻ°ā§āĻŸā§‡ adenoid āĻŦ⧜ āĻšā§Ÿā§‡āĻ›ā§‡â€”āĻāϟāĻŋ āĻāĻ•āĻžāχ antibiotic indication āύ⧟āĨ¤ āϏāĻ¤ā§āϝāĻŋāĻ•āĻžāϰ⧇āϰ AOM āĻšāϞ⧇ drug choice/dose āĻ“āϜāύ āĻ“ history-āύāĻŋāĻ°ā§āĻ­āϰ; āϕ⧇āĻŦāϞ OME āĻšāϞ⧇ antibiotic āϏāĻžāϧāĻžāϰāĻŖāϤ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāĻŋāϤ āύ⧟āĨ¤

2. Xalcort 18 mg — āĻœā§‡āϞāĻ•āĻ°ā§āϟ Identification confidence: 0.94

1. Generic name | āĻœā§‡āύ⧇āϰāĻŋāĻ•

Deflazacort 18 mg — āĻĄā§‡āĻĢāϞāĻžāϜāĻžāĻ•āĻ°ā§āϟāĨ¤

2. Brand name | āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Xalcort 18 mg, Beacon Pharmaceuticals PLC — āĻŦā§€āĻ•āύāĨ¤

3. MedEx alternate brand | āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Defcort, Deflacort, Deflazit (same generic; strength availability varies) — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒāĨ¤

4. MedEx therapeutic class | āĻĨ⧇āϰāĻžāĻĒāĻŋāωāϟāĻŋāĻ• āĻ•ā§āϞāĻžāϏ

Glucocorticoids — āĻ—ā§āϞ⧁āϕ⧋āĻ•āĻ°ā§āϟāĻŋāĻ•ā§Ÿā§‡āĻĄāĨ¤

5. Pharmacological class | āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Systemic corticosteroid — āϏāĻžāϰāĻž āĻļāϰ⧀āϰ⧇ āĻ•āĻžāϜ āĻ•āϰ⧇ āĻāĻŽāύ āĻ¸ā§āĻŸā§‡āĻ°ā§Ÿā§‡āĻĄāĨ¤

6. Use / purpose | āωāĻĻā§āĻĻ⧇āĻļā§āϝ

Severe allergic/inflammatory or other steroid-responsive conditions — āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻĒā§āϰāĻĻāĻžāĻšāϜāύāĻŋāϤ āϰ⧋āϗ⧇āĨ¤

7. Why possibly prescribed here | āĻāχ āϰ⧋āĻ—ā§€āϤ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ•āĻžāϰāĻŖ

āϟāύāϏāĻŋāϞ/āύāĻžāϏāĻžāϞ āĻĒā§āϰāĻĻāĻžāĻš āĻĻā§āϰ⧁āϤ āĻ•āĻŽāĻžāύ⧋āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ āĻšāϤ⧇ āĻĒāĻžāϰ⧇; āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ indication āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ āύ⧟āĨ¤

8. Adverse effects | āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

GI upset, mood/sleep changes, increased glucose, infection risk, adrenal suppression with longer exposure — āĻĒāĻžāĻ•āĻ¸ā§āĻĨāϞ⧀/āϘ⧁āĻŽ/āϰāĻ•ā§āϤ⧇āϰ āϏ⧁āĻ—āĻžāϰ/āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āĻā§āρāĻ•āĻŋāĨ¤

9. Direct MedEx link | āϏāϰāĻžāϏāϰāĻŋ āĻŽā§‡āĻĄā§‡āĻ•ā§āϏ āϞāĻŋāĻ‚āĻ•

Xalcort 18 — MedEx

10. Unit / strip price & other forms | āĻĻāĻžāĻŽ āĻ“ āĻ…āĻ¨ā§āϝ āĻĢāĻ°ā§āĻŽ

ā§ŗ20/tablet; 3 x 10 = ā§ŗ600; 10-tablet equivalent ā§ŗ200 (MedEx page does not explicitly display a strip price). Forms: 6, 18, 24, 30, 36 mg; suspension 6 mg/5 mL.

11. Mechanism of action | āĻ•āĻžāĻ°ā§āϝāĻĒāĻĻā§āϧāϤāĻŋ

Glucocorticoid receptor effects inhibit inflammatory mediator expression — āĻĒā§āϰāĻĻāĻžāĻšā§‡āϰ āϰāĻžāϏāĻžā§ŸāύāĻŋāĻ• āĻŦāĻžāĻ°ā§āϤāĻž āĻ•āĻŽāĻžā§ŸāĨ¤

12. Indications | āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ

Specific severe allergic, autoimmune and inflammatory conditions (not routine isolated adenoid enlargement) — āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϰ⧋āϗ⧇āĨ¤

13. Interactions and contraindications | āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧ

Drug interactions: rifampicin, anticonvulsants, azole antifungals; live vaccines during significant immunosuppression; systemic fungal infection and hypersensitivity need attention.

14. Precautions and warnings | āϏāϤāĻ°ā§āĻ•āϤāĻž

Assess infection, diabetes risk, exposure to other steroids, immunisation status; do not extend or abruptly stop long courses without review.

15. Dose and administration | āĻĄā§‹āϜ āĻ“ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

Handwriting appears 18 mg once in morning for short course; duration unclear. In children dose depends on weight and indication. Guideline does not endorse routine systemic steroids solely for adenoid hypertrophy/OME.

16. Pregnancy and lactation | āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻĻ⧁āĻ—ā§āϧāĻĻāĻžāύ

Not applicable to 10-year-old male; crosses placenta and breastmilk caution for relevant adults.

17. Other compositions / combinations on MedEx | āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•āĻŽā§āĻĒā§‹āϜāĻŋāĻļāύ

6,18,24,30,36 mg tablets and 6 mg/5 mL suspension; same generic non-combination forms.

Critical prescription review | āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž: āĻāĻ•āχ āĻļāĻŋāĻļ⧁āϰ systemic Xalcort + intranasal mometasone āĻāĻ•āϏāĻ™ā§āϗ⧇ āĻĨāĻžāĻ•āϞ⧇ āĻŽā§‹āϟ steroid exposure āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύ; routine adenoid/OME treatment āĻšāĻŋāϏ⧇āĻŦ⧇ systemic steroid āϝāĻĨāĻžāĻ°ā§āĻĨ āύ⧟āĨ¤

3. Paricel 10 mg — āĻĒā§āϝāĻžāϰāĻŋāϏ⧇āϞ (probable) Identification confidence: 0.72

1. Generic name | āĻœā§‡āύ⧇āϰāĻŋāĻ•

Rabeprazole sodium 10 mg — āĻ°â€ā§āϝāĻžāĻŦ⧇āĻĒā§āϰāĻžāϜāϞāĨ¤

2. Brand name | āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Paricel 10 mg EC tablet, ACI Limited; handwritten name not fully definite.

3. MedEx alternate brand | āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Tagus 10 mg and other rabeprazole brands (MedEx generic list check before substitution) — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒāĨ¤

4. MedEx therapeutic class | āĻĨ⧇āϰāĻžāĻĒāĻŋāωāϟāĻŋāĻ• āĻ•ā§āϞāĻžāϏ

Proton Pump Inhibitor — āĻĒā§āϰ⧋āϟāύ āĻĒāĻžāĻŽā§āĻĒ āχāύāĻšāĻŋāĻŦāĻŋāϟāĻžāϰāĨ¤

5. Pharmacological class | āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Gastric acid secretion inhibitor — āĻĒāĻžāĻ•āĻ¸ā§āĻĨāϞ⧀āϰ āĻāϏāĻŋāĻĄ āĻ•āĻŽāĻžāύ⧋ āĻ“āώ⧁āϧāĨ¤

6. Use / purpose | āωāĻĻā§āĻĻ⧇āĻļā§āϝ

GERD, peptic ulcer or defined acid-related symptoms — āĻ…āĻŽā§āϞāϤāĻž/āϰāĻŋāĻĢā§āϞāĻžāĻ•ā§āϏ/āφāϞāϏāĻžāϰāĨ¤

7. Why possibly prescribed here | āĻāχ āϰ⧋āĻ—ā§€āϤ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ•āĻžāϰāĻŖ

Oral steroid/medicine-āĻāϰ āϏāĻ™ā§āϗ⧇ gastric symptoms āϭ⧇āĻŦ⧇ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇; epigastric symptoms documented āύ⧟āĨ¤

8. Adverse effects | āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

Headache, diarrhoea, abdominal pain, nausea; prolonged use may cause mineral deficiency and C. difficile risk — āĻŽāĻžāĻĨāĻžāĻŦā§āϝāĻĨāĻž/āĻĒ⧇āĻŸā§‡āϰ āωāĻĒāϏāĻ°ā§āĻ— āχāĻ¤ā§āϝāĻžāĻĻāĻŋāĨ¤

9. Direct MedEx link | āϏāϰāĻžāϏāϰāĻŋ āĻŽā§‡āĻĄā§‡āĻ•ā§āϏ āϞāĻŋāĻ‚āĻ•

Paricel 10 — MedEx

10. Unit / strip price & other forms | āĻĻāĻžāĻŽ āĻ“ āĻ…āĻ¨ā§āϝ āĻĢāĻ°ā§āĻŽ

ā§ŗ3.51/tablet; ā§ŗ35.10/10-tablet strip; 10 x 10 pack ā§ŗ351. Other: 20 mg EC tablet/capsule.

11. Mechanism of action | āĻ•āĻžāĻ°ā§āϝāĻĒāĻĻā§āϧāϤāĻŋ

Blocks parietal cell H+/K+-ATPase to lower gastric acid — āĻāϏāĻŋāĻĄ āĻ‰ā§ŽāĻĒāĻžāĻĻāύ⧇āϰ āĻšā§‚ā§œāĻžāĻ¨ā§āϤ āϧāĻžāĻĒ āĻŦāĻ¨ā§āϧ āĻ•āϰ⧇āĨ¤

12. Indications | āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ

GERD, ulcers, selected H. pylori regimens, acid hypersecretory conditions — āĻĒāĻžāĻ•āĻ¸ā§āĻĨāϞ⧀āϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϰ⧋āĻ—āĨ¤

13. Interactions and contraindications | āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧ

Drug absorption interactions (ketoconazole/itraconazole), avoid atazanavir; hypersensitivity caution.

14. Precautions and warnings | āϏāϤāĻ°ā§āĻ•āϤāĻž

Not routinely indicated simply for short-course steroid use in a healthy child. Product page contains internally inconsistent paediatric messaging; verify specific formulation indication.

15. Dose and administration | āĻĄā§‹āϜ āĻ“ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

Handwriting may be 1+0+1; this is not confirmed. MedEx paediatric GERD dosing discussion typically once daily by weight; a 10-year-old should not be given twice daily solely on uncertain handwriting.

16. Pregnancy and lactation | āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻĻ⧁āĻ—ā§āϧāĻĻāĻžāύ

Not applicable to 10-year-old male; manufacturer cautions for pregnancy/breastfeeding.

17. Other compositions / combinations on MedEx | āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•āĻŽā§āĻĒā§‹āϜāĻŋāĻļāύ

10 mg EC tablet, 20 mg EC tablet, 20 mg EC capsule; no routine combination confirmed on brand page.

Critical prescription review | āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž: āĻāϟāĻŋ āĻ•āĻžāύ⧇āϰ āĻŦāĻž āĻ…ā§āϝāĻžāĻĄāĻŋāĻ¨ā§Ÿā§‡āĻĄā§‡āϰ āϰ⧋āϗ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύ⧟āĨ¤ āĻ—ā§āϝāĻžāĻ¸ā§āĻŸā§āϰāĻŋāĻ• āωāĻĒāϏāĻ°ā§āĻ—/GERD āύāĻž āĻĨāĻžāĻ•āϞ⧇ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āϝāĻžāϚāĻžāχ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇; ā§§ā§Ļ āĻŦāĻ›āϰ āĻŦ⧟āϏ⧇ formulation āĻāĻŦāĻ‚ dosing āĻŦāĻŋāĻļ⧇āώāĻ­āĻžāĻŦ⧇ āϝāĻžāϚāĻžāχāϝ⧋āĻ—ā§āϝāĨ¤

4. Afrin nasal drops — āφāĻĢāϰāĻŋāύ āύāĻžāϕ⧇āϰ āĻĄā§āϰāĻĒ Identification confidence: 0.89 (brand), <0.5 (strength)

1. Generic name | āĻœā§‡āύ⧇āϰāĻŋāĻ•

Oxymetazoline hydrochloride — āĻ…āĻ•ā§āϏāĻŋāĻŽā§‡āϟāĻžāĻœā§‹āϞāĻŋāύāĨ¤

2. Brand name | āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Afrin nasal drops, Aristopharma Ltd.; concentration handwriting unclear (0.05% adult/â‰Ĩ6y or 0.025% lower strength).

3. MedEx alternate brand | āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Azolin, Congenil, Nasoclin, Oxrin, Nasalox (appropriate matching strength required).

4. MedEx therapeutic class | āĻĨ⧇āϰāĻžāĻĒāĻŋāωāϟāĻŋāĻ• āĻ•ā§āϞāĻžāϏ

Nasal Anti-histamine preparations, Nasal Decongestants & Other Nasal Preparations — MedEx āĻļā§āϰ⧇āĻŖāĻŋāĨ¤

5. Pharmacological class | āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Topical alpha-adrenergic sympathomimetic vasoconstrictor — āύāĻžāϕ⧇āϰ āϰāĻ•ā§āϤāύāĻžāϞāĻŋ āϏāĻ‚āϕ⧁āϚāĻŋāϤāĻ•āĻžāϰ⧀āĨ¤

6. Use / purpose | āωāĻĻā§āĻĻ⧇āĻļā§āϝ

Short-term nasal congestion relief — āϏāĻžāĻŽā§ŸāĻŋāĻ• āύāĻžāĻ• āĻŦāĻ¨ā§āϧ āωāĻĒāĻļāĻŽāĨ¤

7. Why possibly prescribed here | āĻāχ āϰ⧋āĻ—ā§€āϤ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ•āĻžāϰāĻŖ

āύāĻžāϕ⧇āϰ āϭ⧇āϤāϰ⧇āϰ mucosal swelling āĻ•āĻŽāĻŋā§Ÿā§‡ āĻļā§āĻŦāĻžāϏ āύāĻŋāϤ⧇ āϏāĻžāĻšāĻžāĻ¯ā§āϝ āĻ•āϰāĻžāϰ āϜāĻ¨ā§āϝ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

8. Adverse effects | āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

Dryness, burning, rebound congestion, rarely palpitations/BP changes — āύāĻžāĻ• āĻœā§āĻŦāĻžāϞāĻž, āĻŦāĻžāϰāĻŦāĻžāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāϞ⧇ āφāϰāĻ“ āĻŦāĻ¨ā§āϧ āĻšāĻ“ā§ŸāĻžāĨ¤

9. Direct MedEx link | āϏāϰāĻžāϏāϰāĻŋ āĻŽā§‡āĻĄā§‡āĻ•ā§āϏ āϞāĻŋāĻ‚āĻ•

Oxymetazoline nasal preparation — MedEx

10. Unit / strip price & other forms | āĻĻāĻžāĻŽ āĻ“ āĻ…āĻ¨ā§āϝ āĻĢāĻ°ā§āĻŽ

MedEx: Afrin 0.05% 10 mL ā§ŗ70; 0.025% 10 mL ā§ŗ65. Bottle price; strip/unit-tablet price not applicable.

11. Mechanism of action | āĻ•āĻžāĻ°ā§āϝāĻĒāĻĻā§āϧāϤāĻŋ

Alpha-receptor stimulation constricts nasal mucosal arterioles — āύāĻžāϕ⧇āϰ āĻĢā§‹āϞāĻž āĻ•āĻŽāĻžā§ŸāĨ¤

12. Indications | āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ

Symptomatic congestion due to cold/rhinitis/sinusitis — āωāĻĒāϏāĻ°ā§āĻ— āωāĻĒāĻļāĻŽāĨ¤

13. Interactions and contraindications | āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧ

MAO inhibitors or some antidepressants, hypersensitivity, cardiovascular disease/thyroid disease/glaucoma require caution.

14. Precautions and warnings | āϏāϤāĻ°ā§āĻ•āϤāĻž

Rhinitis medicamentosa with repeated/prolonged use; avoid use beyond 3–5 days without clinician assessment.

15. Dose and administration | āĻĄā§‹āϜ āĻ“ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

Concentration and number of drops on photograph cannot be read reliably; do not translate into a usable order until checked on original or pharmacy dispensing label.

16. Pregnancy and lactation | āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻĻ⧁āĻ—ā§āϧāĻĻāĻžāύ

Not applicable to 10-year-old male; generally caution in pregnancy/lactation.

17. Other compositions / combinations on MedEx | āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•āĻŽā§āĻĒā§‹āϜāĻŋāĻļāύ

0.025% and 0.05% nasal-drop preparations; oxymetazoline also exists as nasal sprays from other brands.

Critical prescription review | āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž: āĻļ⧁āϧ⧁ āĻ…āĻ˛ā§āĻĒ āĻĻāĻŋāύ⧇āϰ āωāĻĒāϏāĻ°ā§āĻ—-āωāĻĒāĻļāĻŽā§‡āĨ¤ OME āϏāĻžāϰāĻŋā§Ÿā§‡ āϤ⧋āϞ⧇ āύāĻž; āĻĻā§€āĻ°ā§āϘ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇ rebound congestion āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

5. Momes- nasal spray — āϏāĻŽā§āĻ­āĻŦāϤ Momeson / Momespray Identification confidence: 0.72

1. Generic name | āĻœā§‡āύ⧇āϰāĻŋāĻ•

Mometasone furoate 50 mcg/spray (probable) — āĻŽā§‹āĻŽā§‡āϟāĻžāϏ⧋āύ āĻĢāĻŋāωāĻ°ā§‹ā§Ÿā§‡āϟāĨ¤

2. Brand name | āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Handwritten “Momeâ€Ļ”: Momeson (Incepta) or Momespray (Navana) possible; cannot prove which brand.

3. MedEx alternate brand | āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Metaspray, Metamist, Nasomet, Nasonex, M-Son (same active ingredient/strength).

4. MedEx therapeutic class | āĻĨ⧇āϰāĻžāĻĒāĻŋāωāϟāĻŋāĻ• āĻ•ā§āϞāĻžāϏ

Nasal Steroid Preparations — āύāĻžāϕ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻ¸ā§āĻŸā§‡āĻ°ā§Ÿā§‡āĻĄāĨ¤

5. Pharmacological class | āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Topical corticosteroid / glucocorticoid — āĻ¸ā§āĻĨāĻžāĻ¨ā§€ā§Ÿ āĻĒā§āϰāĻĻāĻžāĻšāύāĻžāĻļāĻ• āĻ¸ā§āĻŸā§‡āĻ°ā§Ÿā§‡āĻĄāĨ¤

6. Use / purpose | āωāĻĻā§āĻĻ⧇āĻļā§āϝ

Allergic rhinitis with nasal congestion and sneezing — āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϤ⧇āĨ¤

7. Why possibly prescribed here | āĻāχ āϰ⧋āĻ—ā§€āϤ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ•āĻžāϰāĻŖ

Coexisting rhinitis or nasal inflammatory swelling management may be reason; allergy has not been documented.

8. Adverse effects | āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

Epistaxis, nasal irritation, headache, rarely septal injury, systemic absorption with higher/long-term dose — āύāĻžāĻ• āĻĻāĻŋā§Ÿā§‡ āϰāĻ•ā§āϤ/āĻœā§āĻŦāĻžāϞāĻžāĨ¤

9. Direct MedEx link | āϏāϰāĻžāϏāϰāĻŋ āĻŽā§‡āĻĄā§‡āĻ•ā§āϏ āϞāĻŋāĻ‚āĻ•

Momeson — MedEx
Momespray — MedEx

10. Unit / strip price & other forms | āĻĻāĻžāĻŽ āĻ“ āĻ…āĻ¨ā§āϝ āĻĢāĻ°ā§āĻŽ

Either Momeson or Momespray 50 mcg/spray: 120 metered sprays bottle ā§ŗ250 (not per strip).

11. Mechanism of action | āĻ•āĻžāĻ°ā§āϝāĻĒāĻĻā§āϧāϤāĻŋ

Anti-inflammatory corticosteroid action reduces local cytokine-mediated inflammation — āύāĻžāϕ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻ•āĻŽāĻžā§ŸāĨ¤

12. Indications | āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ

Allergic rhinitis (age â‰Ĩ2), some nasal polyp indications in adults; off-label benefit may occur in selected adenoid enlargement.

13. Interactions and contraindications | āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧ

Strong CYP3A4 inhibitors can raise systemic steroid exposure; avoid known hypersensitivity; combined steroids warrant review.

14. Precautions and warnings | āϏāϤāĻ°ā§āĻ•āϤāĻž

Correct technique: aim away from nasal septum. Assess epistaxis and recent nasal surgery. High doses and prolonged use may affect growth.

15. Dose and administration | āĻĄā§‹āϜ āĻ“ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

The child (2–11 years) allergic-rhinitis label recommendation is typically one 50 mcg spray into each nostril once daily. The handwritten number of sprays/frequency may be higher or not decipherable; verify before use. This is generic labelled guidance, not authorisation to replace the patient’s order.

16. Pregnancy and lactation | āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻĻ⧁āĻ—ā§āϧāĻĻāĻžāύ

Not applicable to 10-year-old male; pregnancy/lactation risk-benefit assessment for adults.

17. Other compositions / combinations on MedEx | āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•āĻŽā§āĻĒā§‹āϜāĻŋāĻļāύ

50 mcg/spray mometasone nasal brands; other mometasone forms (cream, ointment, inhaled) are not interchangeable for nasal use.

Critical prescription review | āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž: āϝāĻĻāĻŋ ‘āĻĒā§āϰāϤāĻŋ āύāĻžāϕ⧇ ⧍ āϚāĻžāĻĒ āĻĻāĻŋāύ⧇ ⧍ āĻŦāĻžāĻ°â€™ āϞ⧇āĻ–āĻž āĻšā§Ÿā§‡ āĻĨāĻžāϕ⧇, ā§§ā§Ļ āĻŦāĻ›āϰ āĻŦ⧟āϏ⧇ allergic-rhinitis labelled dose-āĻāϰ āĻšā§‡ā§Ÿā§‡ āĻŦ⧇āĻļāĻŋ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āĻĢāĻžāĻ°ā§āĻŽāĻžāϏāĻŋāĻ¸ā§āϟ/āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻžāχāĻŦāĻžāϰ⧇āϰ āϏāĻ™ā§āϗ⧇ āĻ…āĻŦāĻŋāϞāĻŽā§āĻŦ⧇ āĻŽāĻŋāϞāĻŋā§Ÿā§‡ āύ⧇āĻ“ā§ŸāĻž āĻĻāϰāĻ•āĻžāϰāĨ¤

6. Trilock 5 mg — āĻŸā§āϰāĻžāχāϞāĻ• Identification confidence: 0.91

1. Generic name | āĻœā§‡āύ⧇āϰāĻŋāĻ•

Montelukast sodium 5 mg — āĻŽāĻ¨ā§āϟāĻŋāϞ⧁āĻ•āĻžāĻ¸ā§āϟāĨ¤

2. Brand name | āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Trilock 5 mg, Opsonin Pharma Ltd.

3. MedEx alternate brand | āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Monas 5, Montene 5 and other confirmed montelukast brands (verify same formulation) — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒāĨ¤

4. MedEx therapeutic class | āĻĨ⧇āϰāĻžāĻĒāĻŋāωāϟāĻŋāĻ• āĻ•ā§āϞāĻžāϏ

Leukotriene receptor antagonists — āϞāĻŋāωāϕ⧋āĻŸā§āϰāĻŋā§Ÿā§‡āύ āϰāĻŋāϏ⧇āĻĒā§āϟāϰ āĻĒā§āϰāϤāĻŋāϰ⧋āϧāĻ•āĨ¤

5. Pharmacological class | āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Selective CysLT1 receptor antagonist — āύāĻŋāĻ°ā§āĻŦāĻžāϚāĻŋāϤ āϰāĻŋāϏ⧇āĻĒā§āϟāϰ āĻŦā§āϞāĻ•āĻžāϰāĨ¤

6. Use / purpose | āωāĻĻā§āĻĻ⧇āĻļā§āϝ

Persistent asthma prevention and selected allergic rhinitis — āĻšāĻžāρāĻĒāĻžāύāĻŋ/āĻ•āĻŋāϛ⧁ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āωāĻĒāϏāĻ°ā§āĻ—āĨ¤

7. Why possibly prescribed here | āĻāχ āϰ⧋āĻ—ā§€āϤ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ•āĻžāϰāĻŖ

āύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻŦāĻž asthma overlap āϭ⧇āĻŦ⧇ āĻĻ⧇āĻ“ā§ŸāĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇; āύāĻŋāĻļā§āϚāĻŋāϤ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

8. Adverse effects | āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

Headache, abdominal discomfort, and important mood/behaviour/sleep changes; rare suicidal thoughts — āϘ⧁āĻŽ/āφāϚāϰāĻŖ/āĻŽā§‡āϜāĻžāĻœā§‡ āϗ⧁āϰ⧁āϤāϰ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ⧇āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāĨ¤

9. Direct MedEx link | āϏāϰāĻžāϏāϰāĻŋ āĻŽā§‡āĻĄā§‡āĻ•ā§āϏ āϞāĻŋāĻ‚āĻ•

Trilock 5 — MedEx
FDA montelukast boxed warning

10. Unit / strip price & other forms | āĻĻāĻžāĻŽ āĻ“ āĻ…āĻ¨ā§āϝ āĻĢāĻ°ā§āĻŽ

ā§ŗ8.06/tablet, ā§ŗ112.84/14-tablet strip, ā§ŗ338.52/3×14 pack. 4 mg and 10 mg; granules, flash, chewable formulations.

11. Mechanism of action | āĻ•āĻžāĻ°ā§āϝāĻĒāĻĻā§āϧāϤāĻŋ

Blocks leukotriene CysLT1 receptors reducing inflammatory airway responses — āϞāĻŋāωāϕ⧋āĻŸā§āϰāĻŋā§Ÿā§‡āύ⧇āϰ āĻ•āĻžāϜ āφāϟāĻ•āĻžā§ŸāĨ¤

12. Indications | āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ

Asthma prevention, exercise-induced bronchoconstriction prevention, allergic rhinitis — āϰ⧋āϗ⧇āϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻžāĨ¤

13. Interactions and contraindications | āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āύāĻŋāώ⧇āϧ

Hypersensitivity contraindication; interactions with rifampicin/phenobarbital and other enzyme inducers may affect exposure.

14. Precautions and warnings | āϏāϤāĻ°ā§āĻ•āϤāĻž

FDA boxed warning: neuropsychiatric events; for allergic rhinitis reserve when alternatives ineffective or not tolerated. Not indicated for acute asthma attack.

15. Dose and administration | āĻĄā§‹āϜ āĻ“ āĻĒā§āĻ°ā§Ÿā§‹āĻ—

Age 6–14 years: 5 mg orally once daily (confirm tablet formulation and prescriber plan). Handwriting seems nighttime; exact duration unclear.

16. Pregnancy and lactation | āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻĻ⧁āĻ—ā§āϧāĻĻāĻžāύ

Not applicable to 10-year-old male; pregnancy/lactation decisions for relevant adults require medical oversight.

17. Other compositions / combinations on MedEx | āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•āĻŽā§āĻĒā§‹āϜāĻŋāĻļāύ

4 mg, 5 mg, 10 mg tablets; 4 mg granules; 4/5 mg flash tablet; 10 mg chewable tablet per MedEx. No necessary co-formulation.

Critical prescription review | āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž: āĻ…ā§āϝāĻžāĻĄāĻŋāĻ¨ā§Ÿā§‡āĻĄ āĻŦ⧜ āĻšāĻ“ā§ŸāĻžāϰ āϜāĻ¨ā§āϝ āĻāϟāĻŋ routine medicine āύ⧟āĨ¤ āϕ⧇āĻŦāϞ nasal allergy āĻšāϞ⧇ safer alternatives āφāϗ⧇ āĻŦāĻŋāĻŦ⧇āϚāύāĻžāϰ āĻĒāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āϝ⧁āĻ•ā§āϤāĻŋ āĻĨāĻžāĻ•āϤ⧇ āĻšāĻŦ⧇; āĻĒāϰāĻŋāĻŦāĻžāϰāϕ⧇ mood/sleep adverse effects āϜāĻžāύāĻžāϤ⧇ āĻšāĻŦ⧇āĨ¤

12. Bangladesh medicines used by indication | āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļ⧇ āϰ⧋āĻ—āϭ⧇āĻĻ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻ“āώ⧁āϧ⧇āϰ āĻĻā§āĻŦāĻŋāĻ¤ā§€ā§Ÿ āĻŸā§‡āĻŦāĻŋāϞ

āĻāχ āĻŸā§‡āĻŦāĻŋāϞāϟāĻŋ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž-āĻļā§āϰ⧇āĻŖāĻŋāϰ āϤāĻĨā§āϝāĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āϤāĻžāϞāĻŋāĻ•āĻž; āϕ⧋āύāĻ“ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āĻāĻ•āχ āϏāĻ™ā§āϗ⧇ āϏāĻŦ āĻ“āώ⧁āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻžāϰ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āύ⧟āĨ¤ Confidence 0.95

Clinical indication | āĻ…āĻŦāĻ¸ā§āĻĨāĻžPossible generic and Bangladesh brand examples (MedEx) | āĻœā§‡āύ⧇āϰāĻŋāĻ• āĻ“ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄWhy / limitation | āϕ⧇āύ/āϏ⧀āĻŽāĻžāĻŦāĻĻā§āϧāϤāĻž
Confirmed bacterial AOM in selected casesAmoxicillin, amoxicillin/clavulanate (Clacido, Moxaclav)āĻœā§€āĻŦāĻžāϪ⧁ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇; āĻ•āĻžāύ⧇āϰ āĻĒāϰ⧀āĻ•ā§āώāĻž, āĻŦ⧟āϏ, severity, āĻ“āϜāύ āĻ“ antimicrobial history āĻ…āύ⧁āϝāĻžā§Ÿā§€āĨ¤
Confirmed group A streptococcal pharyngitisPenicillin V / amoxicillin (different MedEx brands)āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻŸā§‡āĻ¸ā§āϟ/āϝāĻžāϚāĻžāĻ‡ā§Ÿā§‡āϰ āĻĒāϰ; āĻļ⧁āϧ⧁ tonsils āĻŦ⧜ āĻĻ⧇āϖ⧇āχ antibiotic āύ⧟āĨ¤
Allergic rhinitisMometasone nasal spray (Momeson/Momespray), fluticasone nasal sprayāύāĻžāϕ⧇āϰ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āĻĒā§āϰāϧāĻžāύ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž; dose āĻŦ⧟āϏ āĻ“ product-specificāĨ¤
Short-term severe nasal congestionOxymetazoline (Afrin), saline nasal spray (NaSal/Nosomist)Oxymetazoline āĻ•ā§Ÿā§‡āĻ• āĻĻāĻŋāύ⧇āϰ āĻŦ⧇āĻļāĻŋ āύ⧟; saline supportiveāĨ¤
Coexisting asthma / refractory allergic rhinitisMontelukast (Trilock 5)Asthma indication āĻŦāĻž āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āϝāĻ°ā§āĻĨ allergic rhinitis āĻšāϞ⧇; neuropsychiatric warningāĨ¤
Fever or throat/ear painParacetamol — age/weight-specific brandsāωāĻĒāϏāĻ°ā§āϗ⧇āϰ āϜāĻ¨ā§āϝ; āĻ“āϜāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻāĻŦāĻ‚ āϞāĻŋāĻ­āĻžāϰ⧇āϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻž āĻŦāĻŋāĻŦ⧇āϚāύāĻžāĨ¤
OME aloneNo routine antibiotic, antihistamine, systemic or nasal steroid, decongestantOME-āĻāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžā§Ÿ āϏāĻžāϧāĻžāϰāĻŖāϤ āĻĒāĻ°ā§āϝāĻŦ⧇āĻ•ā§āώāĻŖ, hearing assessment āĻ“ follow-upāĨ¤

13. Doctor-versus-independent diagnosis | āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ Dx āĻŦāύāĻžāĻŽ āĻ¸ā§āĻŦāĻžāϧ⧀āύ Clinical Assessment

🟧 Physician — Original Dx | āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϞ⧇āĻ–āĻž

  • Adeno-Tonsillitis — āĻ…ā§āϝāĻžāĻĄāĻŋāύ⧋-āϟāύāϏāĻŋāϞāĻžāχāϟāĻŋāϏ (0.90)
  • Probable AOM (R?) — āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĄāĻžāύ āĻŽāĻ§ā§āϝāĻ•āĻ°ā§āϪ⧇āϰ āϤ⧀āĻŦā§āϰ āĻĒā§āϰāĻĻāĻžāĻš (0.58)
  • Probable OME (Lt?) — āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻŦāĻžāĻŽ āĻŽāĻ§ā§āϝāĻ•āĻ°ā§āϪ⧇ āϤāϰāϞ āϜāĻŽāĻž (0.72)

🟩 Independent working Dx | āĻ¸ā§āĻŦāĻžāϧ⧀āύ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

  • Radiologically supported mild-to-moderate adenoid hypertrophy with nasopharyngeal airway narrowing (J35.2) â€” āĻŦāĻžā§Ÿā§āĻĒāĻĨ āϏāĻ‚āϕ⧁āϚāĻŋāϤāϏāĻš āĻ…ā§āϝāĻžāĻĄāĻŋāĻ¨ā§Ÿā§‡āĻĄ āĻŦ⧜ (0.96)āĨ¤
  • Clinician-documented adenotonsillitis, activity/etiology unverified â€” āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϞ⧇āĻ–āĻž āĻĒā§āϰāĻĻāĻžāĻš, āĻ•āĻŋāĻ¨ā§āϤ⧁ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻŦāĻž āĻ•āĻžāϰāĻŖ āĻ¸ā§āĻŦāĻžāϧ⧀āύāĻ­āĻžāĻŦ⧇ āĻĒā§āϰāĻŽāĻžāĻŖāĻŋāϤ āύ⧟ (0.76)āĨ¤
  • Possible concomitant AOM / OME — laterality and diagnostic criteria to verify â€” āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ•āĻžāύ⧇āϰ āϏāĻŽāĻ¸ā§āϝāĻž; āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟ (0.60)āĨ¤

Concordance | āĻŽāĻŋāϞ: Physician assessment and X-ray both involve adenoidal disease. Difference | āĻ…āĻŽāĻŋāϞ: X-ray confirms enlarged adenoids, not bacterial infection, tonsillitis, AOM or OME. The prescriber’s ear findings may be based on undocumented otoscopy. It would be improper to label radiographic hypertrophy alone as proven bacterial adenotonsillitis. 0.96

14. Evidence-based management and safety audit | āĻ—āĻžāχāĻĄāϞāĻžāχāύāĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻŦā§āϝāĻŦāĻ¸ā§āĻĨāĻžāĻĒāύāĻž āĻ“ āĻ“āώ⧁āϧ⧇āϰ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž

  • Adenoid hypertrophy | āĻ…ā§āϝāĻžāĻĄāĻŋāĻ¨ā§Ÿā§‡āĻĄ āĻŦ⧜: mild or minimally symptomatic disease → watchful waiting; select coexisting rhinitis may benefit from intranasal corticosteroid; persistent obstructive sleep symptoms/ear morbidity → ENT surgical evaluation. 0.95
  • OME | āĻŽāĻ§ā§āϝāĻ•āĻ°ā§āϪ⧇ āϤāϰāϞ: pneumatic otoscopy/tympanometry; non-at-risk children watchful waiting about 3 months. Systemic antibiotics, systemic/intranasal steroids and decongestants not routinely recommended for OME itself. 0.98
  • AOM | āϤ⧀āĻŦā§āϰ āĻŽāĻ§ā§āϝāĻ•āĻ°ā§āĻŖ āĻĒā§āϰāĻĻāĻžāĻš: verify bulging eardrum/middle ear effusion and symptoms before antibiotics; age/severity-based choices. 0.96
  • Suspected bacterial tonsillitis | āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ āϟāύāϏāĻŋāϞ: history/exam; group A strep testing when indicated. Without confirmatory indication, antibiotics may add harm. 0.96
  • Prescription safety: simultaneous oral and nasal steroids, uncertain high-dose nasal spray instructions, unverified 10-year-old tablet antibiotic dose, possible duplicate-day PPI schedule and montelukast boxed warning require reconciliation. 0.98

15. Investigations and follow-up plan | āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āĻĒāϰ⧀āĻ•ā§āώāĻž, āĻĢāϞ⧋āφāĻĒ āĻ“ āϰ⧇āĻĢāĻžāϰ⧇āϞ

Priority | āĻ…āĻ—ā§āϰāĻžāϧāĻŋāĻ•āĻžāϰAction | āĻ•āϰāĻŖā§€ā§ŸReason | āωāĻĻā§āĻĻ⧇āĻļā§āϝ
1ENT review with child’s original Rx, X-ray and medication strips — āϏāĻŦ āύāĻĨāĻŋ āύāĻŋā§Ÿā§‡ ENT āĻĒ⧁āύāĻ°ā§āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύBrand, strength, dose and ear diagnoses āĻŽāĻŋāϞāĻžāύ⧋āĨ¤
2Pneumatic otoscopy Âą tympanometry — āĻ•āĻžāύ⧇āϰ āĻĒāϰ⧀āĻ•ā§āώāĻžAOM vs OME āϏ⧁āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻĒāĻžāĻ°ā§āĻĨāĻ•ā§āϝ āĻ•āϰāĻžāĨ¤
3PTA Âą age-appropriate hearing assessment — āĻļā§āϰāĻŦāĻŖ āĻĒāϰ⧀āĻ•ā§āώāĻžāĻļā§āϰāĻŦāĻŖ āĻ•āĻŽā§‡ āϗ⧇āϞ⧇ āĻŦāĻž OME āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžā§Ÿā§€ āĻšāϞ⧇; prescription note possible PTA/SRTāĨ¤
4Tonsil and nose examination Âą flexible nasopharyngoscopy — āĻ—āϞāĻž/āύāĻžāĻ• āĻĻ⧇āĻ–āĻžAdenoid obstruction, tonsil grade, rhinitis āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύāĨ¤
5Sleep history Âą polysomnography — āϘ⧁āĻŽ āĻ“ āĻļā§āĻŦāĻžāϏ āĻŽā§‚āĻ˛ā§āϝāĻžā§ŸāύWitnessed apnea, significant snoring or complicated OSA concern āĻĨāĻžāĻ•āϞ⧇āĨ¤
6Consider GAS testing when clinically indicated — āĻ—āϞāĻžāϰ āĻœā§€āĻŦāĻžāϪ⧁ āĻĒāϰ⧀āĻ•ā§āώāĻžāĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϞ tonsillitis-āĻāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āϝāĻžāϚāĻžāχāĨ¤

When urgent: Respiratory distress, cyanosis, profound drowsiness, severe dehydration, postauricular swelling/tenderness, acute facial weakness or severe ear pain with systemic illness → urgent assessment. 0.97

16. Illustrative prescription note and referral | āĻļāĻŋāĻ•ā§āώāĻžāĻŽā§‚āϞāĻ• āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āĻĄā§‡āĻŽā§‹ āĻ“ āϰ⧇āĻĢāĻžāϰ⧇āϞ

ILLUSTRATIVE CLINICAL NOTE — NOT A DISPENSING PRESCRIPTION āĻļāĻŋāĻ•ā§āώāĻžāĻŽā§‚āϞāĻ• āύ⧋āĻŸâ€”āύāϤ⧁āύ āĻ“āώ⧁āϧ⧇āϰ āĻŦ⧈āϧ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āύ⧟

Patient: Md. Mahamud | Age/Sex: 10 years / Male | Source Rx: 18-10-2026

C/C: Not documented — Ask about nasal blockage, snoring, sore throat, otalgia, hearing difficulty.

O/E: Not supplied — Confirm vitals, weight, tonsil grade, nasal examination, bilateral pneumatic otoscopy.

Investigations: Lateral X-ray (12-10-2026): mild–moderate adenoid hypertrophy with narrowed nasopharyngeal airway; consider tympanometry/PTA as indicated.

Dx (prescription-ready, provisional): Adenoid hypertrophy with radiographic nasopharyngeal airway narrowing (J35.2); physician-documented adenotonsillitis; suspected AOM/OME — laterality and clinical confirmation pending.

Plan: ENT reevaluation; confirm eardrum/tonsil findings and body weight; reconcile Clacido, Xalcort, Paricel, Afrin, mometasone spray and Trilock dosing before any further medicines are taken; targeted therapy after confirmation.

Refer to: Consultant Pediatric ENT / Otolaryngologist — evaluate obstructive symptoms, suspected otitis media and hearing status, and determine need for conservative management vs adenoidectomy/other intervention.

Referral note: â€œPlease evaluate this 10-year-old boy with X-ray-confirmed mild-to-moderate adenoid hypertrophy and physician-recorded adenotonsillitis/possible middle-ear disease. Kindly confirm otoscopic and nasopharyngeal findings, hearing status, and appropriateness of the current medications and doses.”

Drug orders: None issued by this educational review. Original doses must be verified by the treating clinician/pharmacist.

17. Overview, next steps and verified references | āϏāĻžāϰāĻžāĻ‚āĻļ, āĻ•āϰāĻŖā§€ā§Ÿ āĻ“ āϝāĻžāϚāĻžāχāĻ•ā§ƒāϤ āϤāĻĨā§āϝāϏ⧂āĻ¤ā§āϰ

Final working conclusion | āĻšā§‚ā§œāĻžāĻ¨ā§āϤ āĻ•āĻžāĻœā§‡āϰ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟: Radiologically Supported Mild-to-Moderate Adenoid Hypertrophy with Nasopharyngeal Airway Narrowing (ICD-10-CM J35.2); Physician-Documented Adenotonsillitis; Suspected Concurrent AOM/OME Requiring Otoscopic Confirmation. Confidence 0.96 for X-ray component; ≤0.76 for other components

  • Today / āĻāĻ–āύ: ear and throat examination, review child’s weight, assess respiratory and sleep symptoms.
  • Before medicines / āĻ“āώ⧁āϧ⧇āϰ āφāϗ⧇: clarify handwritten brand/strength/frequency, especially mometasone spray, antibiotic, oral steroid and PPI; never rely on a photograph to dispense uncertain instructions.
  • Follow-up / āĻĢāϞ⧋āφāĻĒ: Pediatric ENT with tympanometry/age-appropriate hearing testing if suspected middle-ear effusion; surgical need based on symptoms/complications, not X-ray severity alone.

References | āĻĒāĻžāĻ ā§āϝāĻĒ⧁āĻ¸ā§āϤāĻ•, āĻ—āĻžāχāĻĄāϞāĻžāχāύ āĻ“ DOI

Author | āϞ⧇āĻ–āĻ•: Md.Rafiqul Islam Lipu
Reviewed: Saturday, 31 October 2026 | 04:22 PM (Bangladesh Time)
Disclosure: This is a source-preserving, educational clinical analysis, not a substitute for examination or a prescription.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top